WO2015079417A1 - Novel amino pyrimidine derivatives - Google Patents

Novel amino pyrimidine derivatives Download PDF

Info

Publication number
WO2015079417A1
WO2015079417A1 PCT/IB2014/066422 IB2014066422W WO2015079417A1 WO 2015079417 A1 WO2015079417 A1 WO 2015079417A1 IB 2014066422 W IB2014066422 W IB 2014066422W WO 2015079417 A1 WO2015079417 A1 WO 2015079417A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
halogen
fluoro
cyclopropyl
Prior art date
Application number
PCT/IB2014/066422
Other languages
French (fr)
Inventor
Daniela Angst
François GESSIER
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL14821285T priority Critical patent/PL3074386T3/en
Priority to CN201480058515.5A priority patent/CN105683181B/en
Priority to EP20158961.1A priority patent/EP3689865B1/en
Priority to NZ718835A priority patent/NZ718835A/en
Priority to CA2926908A priority patent/CA2926908C/en
Priority to UAA201603623A priority patent/UA117256C2/en
Priority to CN201910288376.XA priority patent/CN110172056B/en
Priority to RS20171206A priority patent/RS56657B1/en
Priority to MX2016006908A priority patent/MX367911B/en
Priority to LTEP14821285.5T priority patent/LT3074386T/en
Priority to KR1020227009823A priority patent/KR102421388B1/en
Priority to EP14821285.5A priority patent/EP3074386B1/en
Priority to CU2016000078A priority patent/CU24384B1/en
Priority to PL17191467T priority patent/PL3299368T3/en
Priority to EP17191467.4A priority patent/EP3299368B1/en
Priority to ES14821285.5T priority patent/ES2655527T3/en
Priority to JP2016535053A priority patent/JP6342495B2/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to MYPI2020002915A priority patent/MY191381A/en
Priority to NO14821285A priority patent/NO3074386T3/no
Priority to MA39055A priority patent/MA39055B1/en
Priority to TN2016000128A priority patent/TN2016000128A1/en
Priority to DK14821285.5T priority patent/DK3074386T3/en
Priority to BR112016010397-1A priority patent/BR112016010397B1/en
Priority to AP2016009158A priority patent/AP2016009158A0/en
Priority to EA201691125A priority patent/EA031218B1/en
Priority to AU2014356069A priority patent/AU2014356069B2/en
Priority to SI201430536T priority patent/SI3074386T1/en
Priority to MYPI2016701223A priority patent/MY179059A/en
Priority to EP23161775.4A priority patent/EP4219478A1/en
Priority to KR1020167013830A priority patent/KR102380539B1/en
Publication of WO2015079417A1 publication Critical patent/WO2015079417A1/en
Priority to ZA2016/02275A priority patent/ZA201602275B/en
Priority to IL244943A priority patent/IL244943B/en
Priority to PH12016500791A priority patent/PH12016500791B1/en
Priority to CR20160244A priority patent/CR20160244A/en
Priority to HK16111636.9A priority patent/HK1223368A1/en
Priority to CY20171101345T priority patent/CY1119705T1/en
Priority to HRP20171999TT priority patent/HRP20171999T1/en
Priority to CY20201100478T priority patent/CY1122924T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention describes new amino pyrimidine derivatives that are good drug candidates.
  • the compounds of the present invention may generally exhibit a selective inhibition of Bruton's tyrosine kinase (Btk).
  • Btk The essential role of Btk in autoimmune disease is underlined by the observations that Btk-deficient mice are protected in standard preclinical models for rheumatoid arthritis (Jansson & Holmdahl 1993), systemic lupus erythematosus (Steinberg et al. 1982), as well as allergic disease and anaphylaxis (Hata et al. 1998). In addition, many cancers and lymphomas express Btk and appear to be dependent on Btk function (Davis et al. 2010). The role of BTK in diseases including autoimmunity, inflammation and cancer has been recently reviewed (Tan et al. 2013; Rickert 2013).
  • Inhibition of Btk activity by the compounds of the present invention may therefore be useful in the treatment of a wide range of disorders, particularly Btk-related diseases or disorders.
  • This may include, but is not limited to autoimmune disorders and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus or vasculitic conditions. It may include, but is not limited to allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD) or conditions caused by delayed or immediate type hypersensitivity and anaphylaxis. It may include, but is not limited to acute or chronic transplant rejection or graft versus host disease.
  • autoimmune disorders and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus or vasculitic conditions. It may include, but is not limited to allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD) or conditions caused by delayed or immediate type hypersensitivity and ana
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
  • R1 is hydrogen, C C 6 alkyl optionally substituted by hydroxy
  • R2 is hydrogen or halogen
  • R3 is hydrogen or halogen
  • R4 is hydrogen
  • R5 is hydrogen or halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R, R', R10 and R1 1 independently from each other stand for H, or C C 6 alkyl optionally substituted by C C 6 alkoxy; or any two of R8, R9, R, R', R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R12 is hydrogen or C C 6 alkyl optionally substituted by halogen or C C 6 alkoxy
  • R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrC f , alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl, C C 6 alkoxy or N,N-di-C C 6 alkyl amino; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by CrC f , alkyl.
  • Embodiment 2 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is halogen
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R and R' are hydrogen
  • R12 is hydrogen or CrCei alkyl optionally substituted by halogen
  • R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrC f , alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 3 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is halogen
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R and R' are hydrogen
  • R12 is hydrogen or CrCei alkyl optionally substituted by halogen
  • R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrC f , alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 4 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, C C 6 alkyl optionally substituted by hydroxy
  • R2 is hydrogen or halogen
  • R3 is hydrogen or halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R and R' are hydrogen
  • R12 is hydrogen or CrCei alkyl optionally substituted by halogen
  • R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrC f , alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 5 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, C C 6 alkyl optionally substituted by hydroxy
  • R2 is hydrogen or halogen
  • R3 is hydrogen or halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R and R' are hydrogen
  • R12 is hydrogen or CrCei alkyl optionally substituted by halogen
  • R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C 6 alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 6 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is halogen
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl;
  • R and R' are hydrogen;
  • R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 7 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is halogen
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8 and R9 independently from each other stand for H, or C C 6 alkyl;
  • R and R' are hydrogen
  • R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C 6 alkyl or C C 6 alkoxy;
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkylenyl oxide optionally substituted by C C 6 alkyl.
  • Embodiment 8 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is halogen
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl
  • R and R' are hydrogen
  • R12 is hydrogen or C ⁇ alkyl optionally substituted by halogen
  • n 0 or 1 ;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy.
  • Embodiment 9 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is hydrogen, or C C 6 alkyl optionally substituted by hydroxy
  • R2 is fluoro
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is halogen
  • R6 and R7 stand independently from each other for H, C C 6 alkyl optionally substituted by hydroxyl, C 3 -C 6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
  • R8 and R9 independently from each other stand for H, or C C 6 alkyl
  • R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C 6 alkyl or C C 6 alkoxy;
  • n 0;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl or C C 6 alkoxy; or C 2 -C 6 alkynyl optionally substituted by C C 6 alkyl or C C 6 alkoxy.
  • Embodiment 10 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
  • R1 is C C 6 alkyl
  • R2 is fluoro
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is fluoro
  • R6 and R7 stand independently from each other for H, C 3 -C 6 cycloalkyl, or halogen;
  • R8, R9, R10 and R1 1 stand for H;
  • R12 is methyl;
  • n 0;
  • R13 is C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl.
  • R1 is methyl or hydroxymethyl
  • R2 is hydrogen or fluoro
  • R3 is hydrogen
  • R1 is methyl or hydroxymethyl and R2 and R3 are independently hydrogen or fluoro;
  • R4 is hydrogen
  • R5 is fluoro
  • R6 is H and R7 is C 3 -C 6 -cycloalkyl and in particular cyclopropyl;
  • R7 is H and R6 is C 3 -C 6 -cycloalkyl and in particular cyclopropyl;
  • R8, R9, RI O and R1 1 stand for H;
  • R12 and any one of R8, R9, R, R',R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, hydroxyl, C C 6 alkyl or C C 6 alkoxy;
  • R8, R9, R10 and R1 1 independently from each other stand for H, or C C 6 alkyl; or any two of R8, R9, R, R', R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
  • R12 is hydrogen and R13 stands for C 2 -C 6 alkenyl optionally substituted by C C 6 alkyl;
  • R12 is methyl
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament. ln another embodiment the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder mediated by Btk.
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is selected from:
  • C1-C6 alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 6 carbon atoms. Unless otherwise provided, it refers to hydrocarbon moieties having 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 to 2 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, sec-butyl, / ' so-butyl, fe/f-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl and the like.
  • C2-C6 alkenyl refers to an unsaturated branched or unbranched hydrocarbon moiety having 2 to 6 carbon atoms. Unless otherwise provided, C2-C6 alkenyl refers to moieties having 2 to 6 carbon atoms, 2 to 5 carbon atoms, or 2 to 4 carbon atoms.
  • alkenyl include, but are not limited to, ethenyl, n-propenyl, / ' so-propenyl, n-butenyl, sec-butenyl, / ' so-butenyl, tert- butenyl, n-pentenyl, isopentenyl, neopentenyl, n-hexenyl, and the like.
  • C 2 -C 6 alkynyl refers to an unsaturated branched or unbranched hydrocarbon moiety having 2 to 6 carbon atoms, containing at least one triple bond, and which is attached to the rest of the molecule by a single bond.
  • C 2 - 4 alkynyl is to be construed accordingly. Examples of C 2 - 6 alkynyl include, but are not limited to, ethynyl, prop-1 -ynyl, but-1 -ynyl, pent-1 -ynyl and penta-1 ,4-diynyl and the like.
  • C C 6 alkoxy refers to alkyl-O-, wherein alkyl is defined herein above.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, fe/f-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like.
  • alkoxy groups have about 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 to 2 carbon atoms.
  • Ci Ci.ealkylamino refers to a moiety of the formula -N(R a )-R a where each R a is a C 1-6 alkyl , which may be the same or different, as defined above.
  • C 3 -C 6 cycloalkyi refers to saturated monocyclic hydrocarbon groups of 3-6 carbon atoms. Cycloalkyi may also be referred to as a carbocyclic ring and vice versa additionally referring to the number of carbon atoms present. Unless otherwise provided, cycloalkyi refers to cyclic hydrocarbon groups having between 3 and 6 ring carbon atoms or between 3 and 4 ring carbon atoms. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 2 -C 6 alkylenyl oxide refers to a branched or unbranched hydrocarbon moiety comprising an epoxy group and having from 2 to 6 carbon atoms.
  • Representative examples include ethylenyl oxide, propylenyl oxide, butylenyl 1 ,2-oxide, butylenyl 2,3-oxide, butylenyl 3,4-oxide, pentylenyl oxide, hexylenyl oxide, and the like.
  • azacyclic ring refers to a saturated or unsaturated monocyclic hydrocarbon group of 3 - 7 carbon atoms as defined for “cycloalkyi", wherein one carbon atom is replaced by a nitrogen atom. It may be also referred to "azacycloalkyl” or “aza hydrocarbon”. Unless otherwise provided, azacycloalkyl refers to cyclic aza- hydrocarbon groups having between 2 and 6 ring carbon atoms and one nitrogen atom, between 2 and 4 ring carbon atoms and one nitrogen atom, or between 2 and 3 ring carbon atoms and one nitrogen atom. Exemplary azacyclic groups include, but are not limited to, aziridinyl, azetidinly, pyrrolidinyl, piperidinyl, azepanyl, dihydroazepinyl and the like.
  • halogen refers to fluoro, chloro, bromo, and iodo.
  • salt refers to an acid addition or base addition salt of a compound of the invention.
  • Salts include in particular “pharmaceutically acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 l respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labeled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single- photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single- photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, de- acetone, d 6 -DMSO.
  • Compounds of the invention i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co- crystals with suitable co-crystal formers.
  • These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163.
  • the invention further provides co-crystals comprising a compound of formula (I).
  • the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by Btk, or (ii) associated with Btk activity, or (iii) characterized by activity (normal or abnormal) of Btk; or (2) reducing or inhibiting the activity of Btk; or (3) reducing or inhibiting the expression of Btk.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Btk; or reducing or inhibiting the expression of Btk partially or completely.
  • the term "subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • treatment refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • a subject is "in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • any asymmetric atom e.g. , carbon or the like
  • any asymmetric atom can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (c/ ' s or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g. , by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g. , by fractional crystallization of a salt formed with an optically active acid, e.g.
  • Racemic products can also be resolved by chiral chromatography, e.g. , high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
  • compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g. , lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. , silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g. , magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g. , starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • diluents e.g. , lactose, dex
  • Tablets may be either film coated or enteric coated according to methods known in the art.
  • compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1 -50%, of the active ingredient.
  • compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier.
  • Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g. , for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and
  • a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g. , vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
  • agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • the compounds of formula I in free form or in salt form exhibit valuable pharmacological properties, e.g. Btk modulating properties, e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
  • Btk modulating properties e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
  • Compounds of the invention may be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable;
  • COPD chronic obstructive pulmonary disease
  • rheumatoid arthritis including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus
  • SOJIA systemic onset juvenile idiopathic arthritis
  • gout pemphigus vulgaris
  • idiopathic thrombocytopenic purpura systemic lupus
  • erythematosus erythematosus
  • multiple sclerosis myasthenia gravis
  • Sjogren's syndrome autoimmune hemolytic anemia
  • vasculitides cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia
  • compounds of the invention may be useful in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
  • autoimmune disorders inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
  • COPD chronic obstructive pulmonary disease
  • compounds of the invention may be useful in the treatment of cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; anf / or Waldenstroem disease.
  • compounds of the invention may be useful in the treatment of chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, and/or Grave's disease.
  • Agents of the invention may be prepared by a reaction sequence involving an alkylation of 4-amino-6-chloro- pyrimidin-5-ol 1 with an alkyl halide 2 using an appropriate base, Suzuki coupling with a boronic ester using an appropriate palladium catalyst, such as bis(triphenylphosphine)- palladium(ll) dichloride, deprotection using an appropriate acid, such as TFA or HCI, followed by amide formation of the ammonium salt or the free amine with an acid using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or with an acid chloride using an appropriate base, such as DIPEA, as shown in
  • compounds of the invention may be prepared by an alternative reaction sequence (shown below) comprising the steps of reacting the amino hydroxypyrimidine 1 with the hydroxyl amino-alkyl-derivative 2' in a Mitsunobu reaction to furnish intermediate 3, which intermediate 3 is then reacted via a Suzuki-coupling to yield intermediate 5, which is then deprotected to yield intermediate 6, which is then amidated with an acid or acid chloride to yield the final product 7 as already described in scheme 1.
  • DIAD Diisopropyl azodicarboxylate
  • DIPEA /V-Diisopropylethylamine
  • T3P Propylphosphonic anhydride
  • Eluent A Water + 0.05% formic acid + 3.75 mM ammonium acetate.
  • Eluent B Acetonitrile + 0.04% formic acid.
  • Agents of the invention may be prepared by a reaction sequence involving an alkylation of 4-amino-6-chloropyrimidin-5-ol (1 ) with an alkyl halide (2) using an appropriate base, Suzuki coupling with a boronic ester (4) usind an appropriate palladium catalyst, such as bis(triphenylphosphine)palladium(ll) dichloride, deprotection using an appropriate acid, such as TFA or HCI to form intermediate 6, which is reacted with an appropriate acid or acid chloride using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or in the case of an acid chloride using a base, such as DIPEA, to yield compound 7, i.e. a compound of the invention, as shown in Scheme 1 :
  • cyclopropylboronic acid (9.68 g, 1 12.69 mmol) and potassium phosphate (35.70 g, 168.00 mmol) in toluene (250 mL) was degassed with argon for 5 min. Then, tricyclohexylphosphine (2.36 g, 8.41 mmol) and water (1 .82 mL, 101 .00 mmol) were added and the mixture was again degassed with argon for 5 min. Palladium(ll) acetate (0.94 g, 4.21 mmol) was added and the reaction mixture was stirred at 100 °C overnight. The mixture was partitioned between EtOAc and water. The suspension was filtered through a pad of Celite.
  • agents of the invention may be prepared by a reaction sequence involving Mitsunobu reaction of 4-amino-6-chloropyrimidin-5-ol with an alcohol of formula 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine; thereupon the reaction sequences of scheme 1 are being carried out, i.e.
  • Example 6 147 mg, 0.290 mmol in THF (1 .0 mL) was added and the reaction mixture was stirred at RT for 5 hr. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (Xterra 150, water/acetonitrile gradient) to afford Example 11 as a white solid after lyophilization.
  • Triphenylphosphine (169 mg, 0.64 mmol) was added to the filtrate.
  • the filtrate was concentrated and the residue was purified by flash chromatography (silica;cyclohexane/EtOAc gradient, 5-40%).
  • the residue was triturated with a mixture of diethyl ether and pentane (1 :1 ) and filtered.
  • the filter cake was washed with pentane and dried in vacuum to afford INT 13 as a white solid.
  • MS (ESI): [M+H] + 406.3, rt 1 .40 min.
  • INT 18 was prepared according to Scheme 2 following a procedure analogous to INT 10 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with (S)-2-(Boc-amino)-1 -propanol in step 1 , and replacing TFA with HCI in step 3 to afford INT 18 as the hydrochloride salt.
  • Example 18 To a solution of Example 18 (152 mg, 0.29 mmol) in THF (10 mL) was added DIPEA (0.200 mL, 1 .15 mmol) followed by di-fe/f-butyl dicarbonate (233 mg, 1 .07 mmol) and 4-(dimethylamino)pyridine (4 mg, 0.033 mmol). The reaction mixture was stirred at RT overnight. More di-fe/f-butyl dicarbonate (100 mg, 0.46 mmol) was added and the reaction mixture was stirred at RT for 1 .5 hr. The mixture was concentrated under reduced pressure. The residue was purified by flash chromatography (silica;
  • INT 23 was prepared following a procedure analogous to INT 2 replacing 1 -bromo-5- fluoro-2-methyl-3-nitro-benzene with acetic acid 2-bromo-6-(6-cyclopropyl-1 -oxo-3,4- dihydro-1 H-isoquinolin-2-yl)-benzyl ester (WO2010/000633).
  • INT 26 was prepared according to Scheme 2 following a procedure analogous to step 3 of Example 6 replacing INT 9 with INT 25.
  • INT 27 was prepared according to Scheme 2 following a procedure analogous to INT 26 replacing INT 24 with INT 8 in step 3, and purifying the TFA salt over a SPE cartridge (PL-HC03 MP resin) to afford INT 27 as the free amine in step 4.
  • the filtrate was directly loaded onto a silica cartridge and purified by flash chromatography (silica; heptane/acetone gradient, 0-80%) to afford a white solid.
  • the residue was triturated in acetonitrile, filtered off, and rinsed with acetonitrile.
  • the solid was dried in vacuum to afford Example 25 as a white solid.
  • INT 28 was prepared following a procedure analogous to WO2002/102790.
  • INT 30 was prepared according to Scheme 2 following a procedure analogous to of Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 29.
  • INT 35 was prepared according to Scheme 2 following a procedure analogous to step 2 of Example 26 replacing INT 28 with (S)-/V-Boc-azetidine-2-carboxylic acid.
  • INT 36 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing A/-Boc-/V-methyl-hydroxyethylamine with INT 35.
  • agents of the invention may be prepared by a reaction sequence involving deprotection e.g. with a Lewis acid of 4,6-dichloro-5-methoxypyrimidine 8 to yield 4,6- dichloro-5-hydroxyoxy-pyrimidine 9, followed by a Mitsunobu reaction of the pyrimidinol with an alcohol compound 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine to yield intermediate 10, followed by a nucleophilic aromatic substitution e.g. with ammonia in water to yield the aminopyrimidine intermediate 3. Thereupon intermediate 3 is converted into a final compound of the invention, i.e.
  • INT 43 was prepared according to Scheme 3 following a procedure analogous to step 2 of Example 6 replacing INT 8 with INT 42.
  • INT 44 was prepared according to Scheme 3 following a procedure analogous to step 3 of Example 6 replacing INT 9 with INT 43 and purifying the crude by flash
  • agents of the invention may be prepared by a reaction sequence involving alkylation of 4,6-dichloro-5-hydroxy-pyrimidine 9 with benzyl bromide using an appropriate base, such as potassium carbonate, followed by nucleophilic aromatic substitution with ammonium hydroxide to yield the aminopyrimidine 12, Suzuki coupling with a boronic ester 4 using an appropriate catalyst, such as bis(triphenylphosphine)- palladium(ll) dichloride to yield the benzylated intermediate 13. Cleavage of the benzyl group, e.g. by hydrogenation, followed by a Mitsunobu reaction of the pyrimidinol with an alcohol of formula 2' using an appropriate azodicarboxylate, such as DIAD, and
  • INT 52 (2.95 g, 6.35 mmol) in THF (30 mL) was added TBAF (1 .0 M in THF, 7.5 mL, 7.50 mmol). The reaction mixture was stirred at RT for 2.5 hr. The mixture was concentrated and the residue was taken up in EtOAc. The organic phase was washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0- 100%) to afford INT 53 as a colorless residue.
  • the inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay.
  • Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express.
  • the assay plates were prepared by addition of 50 nl per well of compound solution in 90 % DMSO.
  • kinase reactions were started by stepwise addition of 4.5 ⁇ per well of peptide/ATP-solution (4 ⁇ FITC-Ahx- TSELKKVVALYDYMPMNAND-NH2, 164 ⁇ ATP) in kinase buffer (50mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta- glycerophosphate, and 10 ⁇ sodium orthovanadate, 18 mM MgCI2, 1 mM MnCI2) and 4.5 ⁇ per well of enzyme solution (6.4nM full-lenght human recombinant BTK) in kinase buffer.
  • peptide/ATP-solution 4 ⁇ FITC-Ahx- TSELKKVVALYDYMPMNAND-NH2, 164 ⁇ ATP
  • kinase buffer 50mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween
  • Kinase reactions were incubated at 30°C for 60 minutes and subsequently terminated by addition of 16 ⁇ per well of stop solution (100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35).
  • Stop solution 100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35.
  • Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide.
  • Inhibition data were calculated by comparison to control reactions without enzyme (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations.
  • the inhibitory activity of the present compounds in blood was assessed in the following in vitro B cell activation assay.
  • Whole blood was collected from the abdominal aorta of anaesthetized adult male Lewis rats and was anticoagulated with 100 U/ml sodium heparin. Blood was then diluted to 50 % with high glucose DMEM
  • compounds of the invention may generally be useful in the treatment of an indication selected from:
  • Autoimmune disorders inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcer
  • glomerolunephritis Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstroem disease.
  • AMR antibody-mediated transplant rejection
  • graft versus host disease B cell-mediated hyperacute, acute and chronic transplant rejection
  • the therapy is selected from a disease which may be treated by an antagonist of Bruton's tyrosine kinase.
  • the invention provides a method of treating a disease which is treated by the modulation of Btk- comprising administration of a therapeutically acceptable amount of a compound of formula (I) or a salt thereof.
  • the disease is selected from the afore-mentioned lists
  • the compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
  • the compound of the present invention may be administered separately, by the same or different route of
  • the compounds of formula (I) may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of alio- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent.
  • the compounds of formula (I) may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a rmTOR inhibitor, e.g.
  • rapamycin 40-O-(2- hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841 , TAFA-93, biolimus-7 or biolimus-9; an ascomycin having immunosuppressive properties, e.g. ABT-281 , ASM981 , etc.; corticosteroids; cyclophosphamide; azathioprene;
  • methotrexate methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N-benzyl-3,4-dihydroxy- benzylidene-cyanoacetamide a-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide
  • mono-citrate also called CP-690,550
  • sphingosine-1 -phosphate receptor modulators such as FTY720 (fingolimod), or compounds disclosed in WO 2005/000833
  • immunosuppressive monoclonal antibodies e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands
  • other immunomodulatory compounds e.g.
  • a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA- 1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g.
  • a compound of formula (I) may be selected from a PI3K inhibitor (e.g. pan, or alpha, beta, gamma, delta selectives), TNF inhibitors, IL1 beta inhibitors, IL17 inhibitors, and inhibitors of IL6 or IL receptor.
  • a PI3K inhibitor e.g. pan, or alpha, beta, gamma, delta selectives
  • TNF inhibitors IL1 beta inhibitors
  • IL17 inhibitors IL6 or IL receptor
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of formula (I) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a disease or condition mediated by Btk kinases.
  • Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s).
  • a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s).
  • composition may comprise a pharmaceutically acceptable excipient, as described above.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I).
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for
  • the combination therapies of the invention the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers.
  • the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
  • the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by Btk kinases, wherein the medicament is prepared for administration with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by Btk , wherein the medicament is administered with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by Btk, wherein the compound of formula (I) is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk , wherein the other therapeutic agent is prepared for administration with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by Btk , wherein the compound of formula (I) is administered with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk, wherein the other therapeutic agent is administered with a compound of formula (I).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention describes new amino pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

Description

Novel Amino Pyrimidine Derivatives
The present invention describes new amino pyrimidine derivatives that are good drug candidates.
The compounds of the present invention may generally exhibit a selective inhibition of Bruton's tyrosine kinase (Btk).
Background of the invention
The essential role of Btk in autoimmune disease is underlined by the observations that Btk-deficient mice are protected in standard preclinical models for rheumatoid arthritis (Jansson & Holmdahl 1993), systemic lupus erythematosus (Steinberg et al. 1982), as well as allergic disease and anaphylaxis (Hata et al. 1998). In addition, many cancers and lymphomas express Btk and appear to be dependent on Btk function (Davis et al. 2010). The role of BTK in diseases including autoimmunity, inflammation and cancer has been recently reviewed (Tan et al. 2013; Rickert 2013).
Summary of the invention
Inhibition of Btk activity by the compounds of the present invention may therefore be useful in the treatment of a wide range of disorders, particularly Btk-related diseases or disorders. This may include, but is not limited to autoimmune disorders and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus or vasculitic conditions. It may include, but is not limited to allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD) or conditions caused by delayed or immediate type hypersensitivity and anaphylaxis. It may include, but is not limited to acute or chronic transplant rejection or graft versus host disease. It may include, but is not limited to cancers of hematopoietic origin or solid tumors, including chronic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma and other B cell lymphomas. More particularly, in embodiment 1 the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
Figure imgf000003_0001
wherein,
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is hydrogen;
R5 is hydrogen or halogen;
or R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R, R', R10 and R1 1 independently from each other stand for H, or C C6 alkyl optionally substituted by C C6 alkoxy; or any two of R8, R9, R, R', R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R12 is hydrogen or C C6 alkyl optionally substituted by halogen or C C6 alkoxy;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl, C C6 alkoxy or N,N-di-C C6 alkyl amino; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by CrCf, alkyl. Embodiment 2 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
or R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
Embodiment 3 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
Embodiment 4 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl. Embodiment 5 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 and R5 are attached to each other and stand for a -CH2-CH2- , or -CH=CH-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
Embodiment 6 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen; R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
Embodiment 7 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8 and R9, independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen;
R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
Embodiment 8 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen; R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen;
R12 is hydrogen or C ^ alkyl optionally substituted by halogen;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy.
Embodiment 9 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is fluoro;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
R8 and R9 independently from each other stand for H, or C C6 alkyl;
R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy.
Embodiment 10 of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein,
R1 is C C6 alkyl;
R2 is fluoro;
R3 is hydrogen;
R4 is hydrogen;
R5 is fluoro;
R6 and R7 stand independently from each other for H, C3-C6 cycloalkyl, or halogen; R8, R9, R10 and R1 1 stand for H; R12 is methyl;
n is 0; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl.
With regard to a compound of formula (I) the following significances represent further embodiments of the invention independently, collectively or in any combination or in any sub-combination thereof:
1. R1 is methyl or hydroxymethyl;
2. R2 is hydrogen or fluoro;
3. R3 is hydrogen
4. R1 is methyl or hydroxymethyl and R2 and R3 are independently hydrogen or fluoro;
5. R4 is hydrogen;
6. R4 together with R5 is -CH2-CH2- , or -CH=CH- ;
7. R5 is fluoro;
8. R6 is H and R7 is C3-C6-cycloalkyl and in particular cyclopropyl;
9. R7 is H and R6 is C3-C6-cycloalkyl and in particular cyclopropyl;
10. R8, R9, RI O and R1 1 stand for H;
1 1 . R12 and any one of R8, R9, R, R',R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, hydroxyl, C C6 alkyl or C C6 alkoxy;
12. R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R, R', R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
13. R12 is hydrogen and R13 stands for C2-C6 alkenyl optionally substituted by C C6 alkyl;
14. n = 0;
15. R12 is methyl.
In another embodiment the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament. ln another embodiment the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder mediated by Btk.
In another embodiment the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is selected from:
N-(3-(5-((1 -Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
(£)-/V-(3-(6-Amino-5-((1 -(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
N-(3-(6-Amino-5-((1-propioloylazetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-
4- cyclopropyl-2-fluorobenzamide;
A/-(3-(6-Amino-5-((1-(but-2-ynoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-((1 -Acryloylpiperidin-4-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
£J-/V-(3-(6-Amino-5-(2-(/ /-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
£J-/V-(3-(6-Amino-5-(2-(4-methoxy-/ /-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylbut-2-ynamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
A/-(2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2- methylphenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methyloxirane-2-carboxamide;
A/-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1 -oxoisoquinolin-2(1 - )-yl)phenyl)pyrimidin-
5- yl)oxy)ethyl)-/V-methylacrylamide;
/V-(3-(5-(2-Acrylamidoethoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide; /V-(3-(6-Amino-5-(2-(/V-ethylaci lamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl^ 4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-(2-fluoroethyl)aci lamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-((1 -Aci lamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-(2-Aci lamidopropoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(but-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)- 4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(/V-methylaci lamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(/V-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(3-(/V-methylaci lamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-((1 -Aci loylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-((1 -(but-2-ynoyl)pyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-2-(3-(5-((1 -Aci loylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-
(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
A/-(2-((4-Amino-6-(3-(6-cyclopropyl-1 -oxo-3, 4-dihydroisoquinolin-2(1 H)-yl)-5-fluoro-2-
(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methylacrylamide;
/V-(3-(5-(((2S,4/?)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl^ fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
2-(3-(5-(((2S,4/?)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
/V-(3-(5-(((2S,4S)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(((2S,4S)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; /V-(3-(5-(((2S,4R)-1-Aci loyl-4-fluoropyrro^
fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-((1 -Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-((1 -propioloylazetidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-2-(3-(5-((1 -Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
(/?)-/V-(3-(5-((1-Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(/?)-/V-(3-(5-((1-Aci loylpiperidin-3-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-(((2/?,3S)-1 -Aci loyl-3-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-y^ fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-(((2S,4/?)-1 -Aci loyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5 fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
and
/V-(3-(5-(((2S,4S)-1 -Aci loyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.
As used herein, the term "C1-C6 alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 6 carbon atoms. Unless otherwise provided, it refers to hydrocarbon moieties having 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 to 2 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, /'so-propyl, n-butyl, sec-butyl, /'so-butyl, fe/f-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl and the like.
As used herein, the term "C2-C6 alkenyl" refers to an unsaturated branched or unbranched hydrocarbon moiety having 2 to 6 carbon atoms. Unless otherwise provided, C2-C6 alkenyl refers to moieties having 2 to 6 carbon atoms, 2 to 5 carbon atoms, or 2 to 4 carbon atoms. Representative examples of alkenyl include, but are not limited to, ethenyl, n-propenyl, /'so-propenyl, n-butenyl, sec-butenyl, /'so-butenyl, tert- butenyl, n-pentenyl, isopentenyl, neopentenyl, n-hexenyl, and the like.
As used herein, the term "C2-C6 alkynyl" refers to an unsaturated branched or unbranched hydrocarbon moiety having 2 to 6 carbon atoms, containing at least one triple bond, and which is attached to the rest of the molecule by a single bond. The term "C2-4alkynyl" is to be construed accordingly. Examples of C2-6alkynyl include, but are not limited to, ethynyl, prop-1 -ynyl, but-1 -ynyl, pent-1 -ynyl and penta-1 ,4-diynyl and the like.
As used herein, the term "C C6 alkoxy" refers to alkyl-O-, wherein alkyl is defined herein above. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, fe/f-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like. Typically, alkoxy groups have about 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 to 2 carbon atoms.
As used herein, the term "di Ci.ealkylamino" refers to a moiety of the formula -N(Ra)-Ra where each Ra is a C1-6alkyl , which may be the same or different, as defined above.
As used herein, the term "C3-C6 cycloalkyi" refers to saturated monocyclic hydrocarbon groups of 3-6 carbon atoms. Cycloalkyi may also be referred to as a carbocyclic ring and vice versa additionally referring to the number of carbon atoms present. Unless otherwise provided, cycloalkyi refers to cyclic hydrocarbon groups having between 3 and 6 ring carbon atoms or between 3 and 4 ring carbon atoms. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
As used herein "C2-C6 alkylenyl oxide" refers to a branched or unbranched hydrocarbon moiety comprising an epoxy group and having from 2 to 6 carbon atoms.
Representative examples include ethylenyl oxide, propylenyl oxide, butylenyl 1 ,2-oxide, butylenyl 2,3-oxide, butylenyl 3,4-oxide, pentylenyl oxide, hexylenyl oxide, and the like.
As used herein, the term "azacyclic" ring refers to a saturated or unsaturated monocyclic hydrocarbon group of 3 - 7 carbon atoms as defined for "cycloalkyi", wherein one carbon atom is replaced by a nitrogen atom. It may be also referred to "azacycloalkyl" or "aza hydrocarbon". Unless otherwise provided, azacycloalkyl refers to cyclic aza- hydrocarbon groups having between 2 and 6 ring carbon atoms and one nitrogen atom, between 2 and 4 ring carbon atoms and one nitrogen atom, or between 2 and 3 ring carbon atoms and one nitrogen atom. Exemplary azacyclic groups include, but are not limited to, aziridinyl, azetidinly, pyrrolidinyl, piperidinyl, azepanyl, dihydroazepinyl and the like.
As used herein, the term "halogen" or "halo" refers to fluoro, chloro, bromo, and iodo.
As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. "Salts" include in particular "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate and trifluoroacetate salts.
Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
The pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36CI, 125l respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H and 14C, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labeled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single- photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, de- acetone, d6-DMSO.
Compounds of the invention, i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co- crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I).
As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
The term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by Btk, or (ii) associated with Btk activity, or (iii) characterized by activity (normal or abnormal) of Btk; or (2) reducing or inhibiting the activity of Btk; or (3) reducing or inhibiting the expression of Btk. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Btk; or reducing or inhibiting the expression of Btk partially or completely. As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or
"treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.
As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
As used herein, the term "a," "an," "the" and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. Any asymmetric atom (e.g. , carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in c/'s- (Z)- or trans- (£)- form.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (c/'s or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g. , by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g. , by fractional crystallization of a salt formed with an optically active acid, e.g. , tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0, 0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g. , high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound of the present invention
(including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water.
The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g. , lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. , silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g. , magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g. , starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
Tablets may be either film coated or enteric coated according to methods known in the art.
Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1 -50%, of the active ingredient.
Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g. , for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and
preservatives.
As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g. , vials), blister packs, and strip packs.
The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
The compounds of formula I in free form or in salt form, exhibit valuable pharmacological properties, e.g. Btk modulating properties, e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
Utility
Compounds of the invention may be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable;
including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus
erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated
vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstroem disease.
In another embodiment, compounds of the invention may be useful in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
In another embodiment, compounds of the invention may be useful in the treatment of cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; anf / or Waldenstroem disease.
In another embodiment, compounds of the invention may be useful in the treatment of chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, and/or Grave's disease.
Methods of synthesizing Amino-pyrimidines
Agents of the invention, i.e. compounds in accordance to the definition of formula (I), may be prepared by a reaction sequence involving an alkylation of 4-amino-6-chloro- pyrimidin-5-ol 1 with an alkyl halide 2 using an appropriate base, Suzuki coupling with a boronic ester using an appropriate palladium catalyst, such as bis(triphenylphosphine)- palladium(ll) dichloride, deprotection using an appropriate acid, such as TFA or HCI, followed by amide formation of the ammonium salt or the free amine with an acid using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or with an acid chloride using an appropriate base, such as DIPEA, as shown in
Scheme 1 below:
Figure imgf000025_0001
Figure imgf000025_0002
Alternatively, compounds of the invention may be prepared by an alternative reaction sequence (shown below) comprising the steps of reacting the amino hydroxypyrimidine 1 with the hydroxyl amino-alkyl-derivative 2' in a Mitsunobu reaction to furnish intermediate 3, which intermediate 3 is then reacted via a Suzuki-coupling to yield intermediate 5, which is then deprotected to yield intermediate 6, which is then amidated with an acid or acid chloride to yield the final product 7 as already described in scheme 1.
Figure imgf000026_0001
1 3
7
EXPERIMENTAL SECTION Abbreviations:
BISPIN: Bis(pinacolato)diboron
Boc t-Butyloxycarbonyl
DCE: Dichloroethane
DCM: Dichloromethane
DIAD: Diisopropyl azodicarboxylate
DIPEA: /V-Diisopropylethylamine
DME: 1 ,2-Dimethoxyethane
DMF: /V,/V-Dimethylformamide
DMSO: Dimethyl sulfoxide
EtOAc: Ethyl acetate
EtOH: Ethanol
hr: Hour
M: Molar
MeOH: Methanol
min: Minute
NaHMDS: Sodium bis(trimethylsilyl)amide
rt: Retention time
RT: Room temperature
SFC: Supercritical fluid chromatography
Smopex-301 : Polymer supported triphenylphosphine
SPE: Solid phase extraction
TBAF: Tetrabutylammonium fluoride
TBDPS: ferf-Butyldiphylsilyl
TBHP: ferf-Butyl hydroperoxide
TBME: ferf-Butyl methyl ether
TEA: Triethylamine
TFA: Trifluoroacetic acid
THF: Tetrahydrofuran
T3P: Propylphosphonic anhydride
XPhos: 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl 1H NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; v, very) and number of protons. Electron Spray Ionization (ESI) mass spectra were recorded on a Waters Acquity SQD mass spectrometer. Mass spectrometry results are reported as the ratio of mass over charge.
UPLC-MS Method:
Waters Acquity UPLC instrument equipped with PDA detector, Waters Acquity SQD mass spectrometer and Waters Acquity HSS T3 1.8 μηη 2.1 x 50 mm column. Peak detection is reported at full scan 210 - 450 nM. Mass spectrometry results are reported as the ratio of mass over charge.
Eluent A: Water + 0.05% formic acid + 3.75 mM ammonium acetate.
Eluent B: Acetonitrile + 0.04% formic acid.
Flow: 1 mL/min
Gradient:
Time [min] % A (Eluent A) % B (Eluent B)
0.00 95 5
1.40 2 98
1.80 2 98
1.90 95 5
2.00 95 5
All reagents, starting materials and intermediates utilized in these Examples are available from commercial sources or are readily prepared by methods known to those skilled in the art. Synthesis of Aminopyrimidine Derivatives
Agents of the invention may be prepared by a reaction sequence involving an alkylation of 4-amino-6-chloropyrimidin-5-ol (1 ) with an alkyl halide (2) using an appropriate base, Suzuki coupling with a boronic ester (4) usind an appropriate palladium catalyst, such as bis(triphenylphosphine)palladium(ll) dichloride, deprotection using an appropriate acid, such as TFA or HCI to form intermediate 6, which is reacted with an appropriate acid or acid chloride using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or in the case of an acid chloride using a base, such as DIPEA, to yield compound 7, i.e. a compound of the invention, as shown in Scheme 1 :
Scheme 1
Figure imgf000029_0001
Figure imgf000030_0001
Example 1
/V-(3-(5-((1 -Aci^loylazetidin-3^l)oxy)-6-aminopyrimidm^
cyclopropyl-2-fluorobenzamide
ino-6-chloropyrimidin-5-yl)oxy)azetidine-1 -carboxylate, INT 1
Figure imgf000030_0002
To a solution of A/-Boc-3-iodoazetidine (6.84 g, 24.16 mmol) in DMF (37 mL) was added 4-amino-6-chloropyrimidin-5-ol (2.00 g, 13.74 mmol) followed by potassium carbonate (5.70 g, 41 .24 mmol). The reaction mixture was stirred at 100 °C for 16 hr. The mixture was diluted with EtOAc and washed with saturated aqueous sodium hydrogen carbonate solution. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with water (2x) and brine (2x), dried over magnesium sulfate, filtered and concentrated. The crude was dried in vacuum for 30 min. The residue was purified by flash chromatography (DCM/MeOH gradient, 0-5%). The isolated residue was triturated with cyclohexane. The resulting off-white solid was filtered off, rinsed with cyclohexane, and dried in vacuum to afford the title compound INT 1 as an off-white solid.
UPLC-MS: MS (ESI): [M+H]+ 301 .0, rt = 0.83 min. 1 H NMR (DMSO-d6): δ (ppm) 7.98 (s, 1 H), 7.34 (br s, 2H), 4.93-4.70 (m, 1 H), 4.23-3.95 (m, 4H), 1 .39 (s, 9H).
(2) 2-(5-Fluoro-2-methyl-3-nitrophenyl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane, INT
Figure imgf000031_0001
To a mixture of 1 -bromo-5-fluoro-2-methyl-3-nitro-benzene (5.0 g, 21.37 mmol) and bis(diphenylphosphino)ferrocenedichloropalladium(ll) (0.78 g, 1 .06 mmol) in dioxane (200 mL) was added BISPIN (8.14 g, 32.05 mmol) followed by potassium acetate (7.34 g, 74.79 mmol). The reaction mixture was stirred at 100 °C for 6 hr. After cooling the brownish mixture was diluted with water (200 mL) and extracted with EtOAc. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and brine (2x), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc 9:1 ) to afford INT 2 as a yellow oil.
1H NMR (DMSO-d6): δ (ppm) 7.79 (d, 1 H), 7.55 (d, 1 H), 2.48 (s, 3H), 1.31 (s, 12H).
5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)aniline, INT 3
Figure imgf000031_0002
To a solution of INT 2 (12.4 g, 44.1 mmol) in EtOAc (300 mL) was added Pd/C 10% (4.0 g). The reaction mixture was hydrogenated at room temperature and normal pressure for 18 hr. The mixture was filtered over Kieselgur (Supelco) and the filtrate was
concentrated. The residue was purified by flash chromatography (silica, EtOAc) to afford INT 3 as a beige solid.
MS (ESI): 252.2 [M+H]+, 1 H NMR (DMSO-d6): δ (ppm) 6.52-6.46 (m, 2H), 5.13 (br s, 2H), 2.17 (s, 3H), 1 .29 (s, 12H). -cyclopropyl-2-fluorobenzoate, INT 4
Figure imgf000032_0001
A mixture of methyl 4-bromo-2-fluorobenzoate (20.00 g, 85.82 mmol),
cyclopropylboronic acid (9.68 g, 1 12.69 mmol) and potassium phosphate (35.70 g, 168.00 mmol) in toluene (250 mL) was degassed with argon for 5 min. Then, tricyclohexylphosphine (2.36 g, 8.41 mmol) and water (1 .82 mL, 101 .00 mmol) were added and the mixture was again degassed with argon for 5 min. Palladium(ll) acetate (0.94 g, 4.21 mmol) was added and the reaction mixture was stirred at 100 °C overnight. The mixture was partitioned between EtOAc and water. The suspension was filtered through a pad of Celite. The phases of the filtrate were separated, the aqueous layer was back-extracted with EtOAc. The organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate solution and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (cyclohexane/EtOAc gradient, 0-15%) to afford INT 4 as an orange oil. UPLC-MS: MS (ESI): [M+H]+ 195.0, rt = 1.1 1 min. 1 H NMR (CDCI3): δ (ppm) 7.83 (t, 1 H), 6.90 (d, 1 H), 6.79 (d, 1 H), 3.92 (s, 3H), 2.00-1 .96 (m, 1 H), 1 .15-1 .03 (m, 2H), 0.84-0.73 (m, 2H).
(5) 4-Cyclopropyl-2-fluoro-/ /-(5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)phenyl)benzamide, INT 5
Figure imgf000033_0001
To a solution of INT 3 (5.88 g, 23.41 mmol) and INT 4 (5.00 g, 25.70 mmol) in THF (200 mL) at 0°C was added dropwise NaHMDS solution (1 M in THF, 35.1 ml_, 35.10 mmol). The reaction mixture was stirred at RT for 2 hr, then additional NaHMDS solution (1 M in THF, 5.0 mL, 5.00 mmol) was added. After stirring for another hour more NaHMDS solution (1 M in THF, 5.0 mL, 5.00 mmol) was added and the mixture was stirred for an additional 2 hr. The mixture was diluted with EtOAc and washed with saturated aqueous sodium hydrogen carbonate solution and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated. The crude was suspended in EtOAc and filtered. The collected solid was washed with EtOAc and dried in vacuum to afford compound INT 5 as a beige solid.
UPLC-MS: MS (ESI): [M+H]+ 414.2, rt = 1.45 min. 1 H NMR (DMSO-d6): δ (ppm) 9.70 (br s, 1 H), 7.62 (t, 1 H), 7.51 (d, 1 H), 7.19 (dd, 1 H), 7.10-7.00 (m, 2H), 2.37 (s, 3H), 2.06- 1.96 (m, 1 H), 1 .31 (s, 12H), 1 .08-0.99 (m, 2H), 0.82-0.73 (m, 2H).
(6) fe/f-Butyl 3-((4-amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2- oxy)azetidine-1 -carboxylate, INT 6
Figure imgf000033_0002
To a solution of INT 1 (500 mg, 1 .66 mmol) in DME (8.4 mL) and water (1 .2 mL) was added INT 5 (756 mg, 1 .83 mmol) followed by aqueous sodium carbonate solution (1 M, 4.99 mL, 4.99 mmol). The mixture was degassed with argon for 10 min, then
bis(triphenylphosphine)palladium(ll) dichloride (58.3 mg, 0.083 mmol) was added. The reaction mixture was stirred for 10 min at 1 10 °C in a microwave reactor. More INT 5 (137 mg, 0.33 mmol) was added. The reaction mixture was stirred at 1 10 °C for an additional 10 min in a microwave reactor. The mixture was partitioned between EtOAc and saturated aqueous sodium hydrogen carbonate solution. The solid was filtered off, washed with water and EtOAc, and dried in vacuum to afford compound INT 6 as an off- white solid. The mother liquor of the filtration was transferred in an extraction funnel and the layers were separated. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-100%) to afford more INT 6 as an off-white solid.
UPLC-MS: MS (ESI): [M+H]+ 552.3, rt = 1.15 min. 1 H NMR (DMSO-d6): δ (ppm) 9.86 (s, 1 H), 8.19 (s, 1 H), 7.66 (t, 1 H), 7.58 (d, 1 H), 7.21 -6.91 (m, 5H), 4.31-4.16 (m, 1 H), 3.77- 3.46 (m, 4H), 2.08-1.99 (overlapping s, 3H and m, 1 H), 1 .31 (s, 9H), 1 .12-0.98 (m, 2H), 0.87-0.73 (m, 2H).
(7) A/-(3-(6-Amino-5-(azetidin-3-yloxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- amide, INT 7
Figure imgf000034_0001
To a solution of INT 6 (100 mg, 0.18 mmol) in DCM (2.0 mL) was added TFA (0.210 mL, 2.72 mmol) dropwise. The reaction mixture was stirred at RT overnight. The mixture was concentrated and the residue was dried in vacuum to afford crude INT 7 as the TFA salt as a brown oil.
UPLC-MS: MS (ESI): [M+H]+ 452.3, rt = 0.73 min. 1 H NMR (DMSO-d6): δ (ppm) 10.04 (s, 1 H), 8.84 (s, br, 2H), 8.63 (s, 1 H), 8.56 (s, br, 2H), 7.73-7.61 (m, 2H), 7.32-7.24 (m, 1 H), 7.14-7.03 (m, 2H), 4.54-45 (m, 1 H), 3.92-3.46 (m, br, 4H), 2.10-2.01 (overlapping s, 3H and m, 1 H), 1 .12-1 .03 (m, 2H), 0.83-0.77 (m, 2H).
(8) /V-(3-(5-((1 -Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
To a solution of acrylic acid (73 mg, 1.02 mmol) in DMF (1.5 mL) was added DIPEA (0.47 mL, 2.71 mmol) followed by T3P solution (50% in DMF) (0.51 mL, 0.88 mmol). The mixture was stirred at RT for 20 min. To a solution of INT 7 (containing 2.5 eq TFA) (499 mg, 0.68 mmol) and DIPEA (0.36 mL, 2.03 mmol) in DMF (5.3 mL) at 0 °C was added dropwise the above solution. The reaction mixture was stirred at 0 °C for 90 min. The mixture was diluted with EtOAc and washed with saturated aqueous sodium hydrogen carbonate solution. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with water and brine (2x), dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 0-10%) to afford the title compound Example 1 as a white solid after trituration with diethyl ether.
UPLC-MS: MS (ESI): [M+H]+ 506.2, rt = 0.93 min. 1 H NMR (DMSO-cf6): δ (ppm) 9.89 (s, 1 H), 8.2 (s, 1 H), 7.66 (t, 1 H), 7.54 (d, 1 H), 7.2-7.0 (m, 5H), 6.15 (dd, 1 H), 6.02 (dd, 1 H), 5.61 (dd, 1 H), 4.37-4.29 (m, 1 H), 4.1 1 -3.95 (m, 2H), 3.8-3.66 (m, 2H), 2.08-1 .99 (overlapping s, 3H and m, 1 H), 1.08-1 .02 (m, 2H), 0.83-0.76 (m, 2H).
Example 2
(£)-/V-(3-(6-Amino-5-((1 -(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000035_0001
The title compound was prepared according to Scheme 1 following a procedure analogous to Example 1 replacing acrylic acid with (£)-but-2-enoic acid in step 8. UPLC-MS: MS (ESI): [M+H]+ 520.2, rt = 0.97 min.
Example 3
/V-(3-(6-Amino-5-((1-propioloylazetidin-3-yl')oxy')pyrimidin-4-yl')-5-fluoro-2-methylphenyl')-
4-cvclopropyl-2-fluorobenzamide
Figure imgf000036_0001
The title compound was prepared according to Scheme 1 following a procedure analogous to Example 1 replacing acrylic acid with propiolic acid in step 8.
UPLC-MS: MS (ESI): [M+H]+ 504.2, rt = 0.95 min.
Example 4
/V-(3-(6-Amino-5-((1-(but-2-vnoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000036_0002
The title compound was prepared according to Scheme 1 following a procedure analogous to Example 1 replacing acrylic acid with 2-butynoic acid in step 8.
UPLC-MS: MS (ESI): [M+H]+ 518.2, rt = 0.97 min.
Example 5
/V-(3-(5-((1 -Acryloylpiperidin-4-yl')oxy')-6-aminopyrimidin-4-yl')-5-fluoro-2-methylphenyl')-4- cyclopropyl-2-fluorobenzamide
Figure imgf000037_0001
The title compound was prepared according to Scheme 1 following a procedure analogous to Example 1 replacing A/-Boc-3-iodoazetidine with A/-Boc-4-bromopiperidine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 534.2, rt = 0.94 min.
Alternatively, agents of the invention may be prepared by a reaction sequence involving Mitsunobu reaction of 4-amino-6-chloropyrimidin-5-ol with an alcohol of formula 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine; thereupon the reaction sequences of scheme 1 are being carried out, i.e. the Suzuki coupling with a boronic ester using an appropriate catalyst, such as bis(triphenyl- phosphine)-palladium(l l) dichloride, deprotection using an appropriate acid, such as TFA or HCI, followed by amide formation of the ammonium salt or the free amine with an acid and using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DI PEA, or with an acid chloride using an appropriate base, such as DIPEA, to yield a compound of the invention, i.e. a compound of formula 7, as shown in Scheme 2 below:
Scheme 2
Figure imgf000038_0001
1 3
7
Example 6
/V-(3-(6-Amino-5-(2-(/V-methylaci^lamido)ethoxy)pyrimidin-4-vn-5-flu
methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000039_0001
-Butyl (2-((4-amino-6-chloropyrimidin-5-yl)oxy)ethyl)(methyl)carbamate, INT 8
Figure imgf000039_0002
To a solution of 4-amino-6-chloropyrimidin-5-ol (content 90%, 2.00 g, 12.37 mmol) in THF (120 mL) was added /V-Boc-/V-methyl-2-hydroxyethylamine (6.07 g, 34.64 mmol) followed by SMOPEX-301 (1 mmol/g, 30.90 g, 30.90 mmol). Then, a solution of DIAD (6.01 mL, 30.52 mmol) in THF (20 mL) was added slowly. The reaction mixture was stirred at 60 °C for 3 hr. The mixture was filtered through a pad of Celite. The filtrate was concentrated to afford an oil which was triturated with EtOAc and a white precipitate was formed. The solid was filtered off to afford INT 8. The mother liquor was concentrated and the residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0- 100%) to afford more INT 8 as a beige solid.
UPLC-MS: MS (ESI): [M+H]+ 303.1 , rt = 0.86 min. 1 H NMR (DMSO-d6): δ (ppm) 7.97 (s, 1 H), 7.26 (s, br, 2H), 4.02-3.93 (m, 2H), 3.54 (t, 2H), 2.89 (s, br, 3H), 1.39 (s, 9H).
(2) fe/f-Butyl (2-((4-amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2- methylphenyl)pyrimidin-5-yl)oxy)ethyl)(methyl)carbamate, INT 9
Figure imgf000040_0001
To a solution of INT 8 (447 mg, 1 .48 mmol) in DME (7.0 mL) and water (1 .0 mL) was added INT 5 (638 mg, 1 .54 mmol) followed by aqueous sodium carbonate solution (1 M, 4.21 mL, 4.21 mmol). The mixture was degassed with argon for 10 min and
bis(triphenylphosphine)palladium(ll) dichloride (49.2 mg, 0.070 mmol) was added. The reaction mixture was stirred at 1 10 °C for 10 min in a microwave reactor. More INT 5 (232 mg, 0.56 mmol) was added and the reaction mixture was stirred at 1 10 °C for an additional 15 min in a microwave reactor. The mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-100%) to afford INT 9 as an off-white solid.
UPLC-MS: MS (ESI): [M+H]+ 554.3, rt = 1.21 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 9.76 (s, 1 H), 8.19 (s, 1 H), 7.74-7.53 (m, 2H) 7.20-6.85 (m, 5H), 3.57-3.48 (m, 2H), 3.29- 3.15 (m, 2H), 2.58 (s, 3H), 2.08-1 .99 (overlapping s, 3H and m, 1 H), 1 .34 and 1 .28 (s, 9H), 1 .10-1.02 (m, 2H), 0.84-0.77 (m, 2H).
(3) A/-(3-(6-Amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2- pyl-2-fluorobenzamide, INT 10
Figure imgf000040_0002
To a solution of INT 9 (335 mg, 0.61 mmol) in DCM (5.0 mL) was added TFA (0.47 mL, 6.05 mmol). The reaction mixture was stirred at RT for 15 hr. The mixture was concentrated under reduced pressure. The residue was dried in vacuum to afford INT 10 as theTFA salt as a brown oil.
UPLC-MS: MS (ESI): [M+H]+ 454.3, rt = 0.73 min. 1 H NMR (DMSO-d6): δ (ppm) 10.02 (s, 1 H), 9.07-8.13 (s, v br, number of H cannot be assigned), 8.58 (s, 1 H), 8.51 (s, br, 2H), 7.71-7.61 (m, 2H), 7.29-7.22 (m, 1 H), 7.14-7.05 (m, 2H), 3.75-3.65 (m, 2H), 3.16-3.07 (m, 2H), 2.48 (s, 3H, overlapping with solvent peak), 2.12 (s, 3H), 2.10-1.99 (m, 1 H), 1.1 1-1 .03 (m, 2H), 0.83-0.76 (m, 2H).
(4) /V-(3-(6-Amino-5-(2-(/V-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
To a solution of acrylic acid (62 mg, 0.87 mmol) in DMF (4.0 mL) was added DIPEA (0.302 mL, 1 .73 mmol) followed by T3P solution (50% in DMF) (0.438 mL, 0.750 mmol). The mixture was stirred at RT for 30 min. To a solution of INT 10 (containing 3.0 eq TFA, content 90%, 510 mg, 0.577 mmol) and DIPEA (0.302 mL, 1 .731 mmol) in DMF (2.0 mL) at 0 °C was added dropwise the above solution. The reaction mixture was stirred at 0 °C for 30 min. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water (2x) and brine (2x), dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica;
DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 0-9%) to afford the title compound Example 6 as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 508.3, rt = 0.95 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 9.77 and 9.56 (s, total 1 H), 8.25-8.14 (m, 1 H), 7.79-7.50 (m, 2H), 7.17-6.93 (m, 5H), 6.70-6.55 (m, 1 H), 6.06 (t, 1 H), 5.59 (d, 1 H), 3.63-3.40 (m, 4H), 2.80 and 2.49 (s, total 3H, peak at 2.49 overlapping with solvent peak), 2.09-1 .93 (m, 4H), 1 .1 1 -1.00 (m, 2H), 0.85-0.76 (m, 2H). Example 7
^/V-(3-(6-Amino-5-(2-(/V-methylbut-2-enamido ^
methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000042_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing acrylic acid with (£)-but-2-enoic acid in step 4. UPLC-MS: MS (ESI): [M+H]+ 522.2, rt = 0.97 min.
Example 8
A/-(3-(6-Amino-5-(2-(/ /-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000042_0002
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing acrylic acid with propiolic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 506.3, rt = 0.95 min. Example 9 iE^-(3-(6-Amino-5-(2-(4-methoxy-/V-m
fluoro-2-methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000043_0001
(1 ) A/-(3-(6-Amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2- pyl-2-fluorobenzamide, INT 11
Figure imgf000043_0002
To a solution of INT 9 (2.50 g, 4.52 mmol) in DCM (30 mL) was added HCI (2 M in diethyl ether, 20.0 mL, 40.00 mmol). The reaction mixture was stirred at RT for 4 hr. The mixture was concentrated under reduced pressure and the residue was dried in vacuum to afford INT 11 as the hydrochloride salt as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 454.2, rt = 0.70 min. 1 H NMR (MeOD-d3): δ (ppm) 8.60 (s, 1 H), 7.82 (t, 1 H), 7.69-7.62 (m, 1 H), 7.41-7.36 (m, 1 H), 7.10 (d, 1 H), 7.02 (d, 1 H), 4.10- 3.80 (m, br, 2H), 3.39-3.20 (m, 2H), 2.70 (s, 3H), 2.26 (s, 3H), 2.1 1-1 .99 (m, 1 H), 1.19- 1.07 (m, 2H), 0.89-0.77 (m, 2H).
(2) £J-/V-(3-(6-Amino-5-(2-(4-methoxy-/ /-methylbut-2-enamido)ethoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide The title compound was prepared following a procedure analogous to step 4 of Example 6 replacing INT 10 with INT 11 (hydrochloride salt) and replacing acrylic acid with (E)-A- methoxy-but-2-enoic acid.
UPLC-MS: MS (ESI): [M+H]+ 552.2, rt = 0.93 min.
Example 10
A/-(3-(6-Amino-5-(2-(/ /-methylbut-2-vnamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000044_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 520.2, rt = 0.96 min.
Example 11
/V-(2-((4-Amino-6-(3-(4-cvclopropyl-2-fluorobenzamido)-5-fluoro-2- methylphenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methyloxirane-2-carboxamide
Figure imgf000044_0002
To a solution of TBHP (5.5 M in decane, 0.079 mL, 0.434 mmol) in THF (2.0 mL) at -78 °C was added n-butyl lithium (2.5 M in hexane, 0.145 mL, 0.362 mmol). The mixture was stirred at -78 °C for 10 min. Then, a solution of Example 6 (147 mg, 0.290 mmol) in THF (1 .0 mL) was added and the reaction mixture was stirred at RT for 5 hr. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (Xterra 150, water/acetonitrile gradient) to afford Example 11 as a white solid after lyophilization.
UPLC-MS: MS (ESI): [M+H]+ 524.4, rt = 0.88 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 9.83 and 9.58 (s, total 1 H), 8.26-8.15 (m, 1 H), 7.78-7.61 (m, 1 H), 7.61 -7.48 (m, 1 H), 7.22-6.90 (m, 5H), 3.84-3.39 (m, 5H), 2.89 (s, 1.2H), 2.87-2.76 (m, 1 H), 2.71 -2.61 (m, 1 H), 2.44 (s, 1 .8H, overlapping with solvent peak), 2.10-1.93 (m, 4H), 1.12-0.99 (m, 2H), 0.87-0.74 (m, 2H).
Example 12
/V-(2-((4-Amino-6-(3-(6-cvclopropyl-8-fluoro-1 -oxoisoquinolin-2(1 - )-yl)phenyl)pyrimidin-
5-yl)oxy)ethyl)-/V-methylacrylamide
Figure imgf000045_0001
-(3-Chlorophenyl)-6-cyclopropyl-8-fluoroisoquinolin-1 (2H)-one, INT 12
Figure imgf000045_0002
A mixture of 1 -chloro-3-iodobenzene (0.439 ml, 3.54 mmol), 6-cyclopropyl-8-fluoro- isoquinolin-1 (2H)-one (600 mg, 2.95 mmol), ethyl 2-oxocyclohexanecarboxylate (0.094 ml_, 0.591 mmol) and cesium carbonate (2020 mg, 6.20 mmol) in DMSO (15 mL) was degassed with argon for 5 min. Copper(l) iodide (1 12 mg, 0.59 mmol) was added, the reaction flask was sealed, the mixture stirred at 120 °C for 16 hr. The mixture was cooled to RT and diluted with EtOAc (100 mL). The resulting slurry was filtered over Hyflo and the filter cake was washed with EtOAc. The filtrate was concentrated and the residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 5- 40%) to afford INT 12 as a yellow solid.
UPLC-MS: MS (ESI): [M+H]+ 314.1 , rt = 1.25 min. 1 H NMR (DMSO-d6): δ (ppm) 7.61 (s, 1 H), 7.59-7.50 (m, 2H), 7.48-7.40 (m, 2H), 7.26 (s, 1 H), 6.99 (d, 1 H), 6.60 (d, 1 H), 2.12- 2.02 (m, 1 H), 1 .14-1 .05 (m, 2H), 0.92-0.83 (m, 2H).
(2) 6-Cyclopropyl-8-fluoro-2-(3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- (2H)-one, INT 13
Figure imgf000046_0001
A mixture of INT 12 (808 mg, 2.58 mmol), BISPIN (981 mg, 3.86 mmol), X-Phos (123 mg, 0.26 mmol) and potassium acetate (758 mg, 7.73 mmol) in dioxane (13 mL) was degassed under argon for 5 min. Tris(dibenzylideneacetone)dipalladium(0) (1 18 mg, 0.13 mmol) was added and the reaction flask was sealed. The reaction mixture was stirred at 105 °C for 2 hr. The mixture was cooled to RT, filtered over Hyflo and the filter cake was washed with EtOAc. Triphenylphosphine (169 mg, 0.64 mmol) was added to the filtrate. The filtrate was concentrated and the residue was purified by flash chromatography (silica;cyclohexane/EtOAc gradient, 5-40%). The residue was triturated with a mixture of diethyl ether and pentane (1 :1 ) and filtered. The filter cake was washed with pentane and dried in vacuum to afford INT 13 as a white solid. UPLC-MS: MS (ESI): [M+H]+ 406.3, rt = 1 .40 min. 1 H NMR (DMSO-d6): δ (ppm) 7.75- 7.70 (m, 1 H), 7.64 (s, 1 H), 7.59-7.54 (m, 2H), 7.44 (d, 1 H), 7.25 (s, 1 H), 6.98 (d, 1 H), 6.59 (d, 1 H), 2.1 1 -2.02 (m, 1 H), 1 .31 (s, 12H), 1 .13-1 .06 (m, 2H), 0.91 -0.84 (m, 2H).
(3) 2-(3-(6-Amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)phenyl)-6-cyclopropyl-8- -one, INT 14
Figure imgf000047_0001
Intermediate INT 14 was prepared according to Scheme 2 following a procedure analogous to steps 2 and 3 of Example 6 replacing INT 5 with INT 13 in step 2, and by doing a basic work-up in step 3 to afford INT 14 as the free amine.
UPLC-MS: MS (ESI): [M+H]+ 446.3, rt = 0.71 min. 1 H NMR (DMSO-d6): δ (ppm) 8.21 (s, 1 H), 8.13-8.02 (m, 2H), 7.63 (t, 1 H), 7.51 (t, 2H), 7.45-7.31 (m, 2H), 7.27 (s, 1 H), 6.99 (d, 1 H), 6.62 (d, 1 H), 3.73-3.64 (m, 2H), 2.73-2.64 (m, 2H), 2.23 (s, 3H), 2.12-2.03 (m, 1 H), 1 .14-1 .06 (m, 2H), 0.92-0.83 (m, 2H).
(4) A/-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1 -oxoisoquinolin-2(1 H)- yl)phenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methylacrylamide
To a solution of INT 14 (73 mg, 0.16 mmol) and DIPEA (86 μΙ, 0.492 mmol) in THF (1 .6 mL) at -20 °C was added acryloyi chloride (14 μΙ, 0.172 mmol). The reaction mixture was stirred at -20 °C for 10 min. The mixture was diluted with aqueous sodium carbonate solution (2 M) and water and extracted with DCM (3x). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by SFC to afford Example 12 as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 500.4, rt = 0.93 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 8.26-8.18 (m, 1 H), 8.04-7.87 (m, 2H), 7.64-7.43 (m, 3H), 7.27 (s, 1 H), 7.16-7.03 (m, 2H), 7.03-6.95 (m, 1 H), 6.85 and 6.69 (dd, total 1 H), 6.65-6.58 (m, 1 H), 6.09 (d, 1 H), 5.60 (t, 1 H), 3.84-3.72 (m, 2H), 3.71 -3.60 (m, 2H), 3.04 and 2.76 (s, total 3H), 2.13-2.02 (m, 1 H), 1.16-1 .05 (m, 2H), 0.93-0.83 (m, 2H).
Example 13
/V-(3-(5-(2-Aci^lamidoethoxy)-6-aminopyrirnidin-4-yl')-5-fluoro-2-methylphenyl')-4- cvclopropyl-2-fluorobenzamide
Figure imgf000048_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with /V-Boc-2- hydroxyethylamine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 494.2, rt = 0.91 min.
Example 14
/V-(3-(6-Amino-5-(2-(/V-ethylaci^lamido)ethoxy)pyrirnidin-4-yl')-5-fluoro-2-rnethylphenyl')-
4-cvclopropyl-2-fluorobenzamide
Figure imgf000048_0002
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with N-Boc-N- ethyl-2-hydroxyethylamine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 522.4, rt = 0.99 min.
Example 15
A/-(3-(6-Amino-5-(2-(/ /-(2-fluoroethyl)acrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000049_0001
(1 ) fe/f-Butyl (2-(benzyloxy)ethyl)(2-fluoroethyl)carbamate, INT 15
Figure imgf000049_0002
To a solution of 2-fluoroethanamine hydrochloride (4.35 g, 43.71 mmol) and 2- (benzyloxy)-acetaldehyde (6.04 g, 5.65 ml_, 40.22 mmol) in MeOH (70 mL) was added sodium triacetoxyborohydride (10.44 g, 49.26 mmol). The reaction mixture was stirred at RT for 4 hr. The mixture was concentrated. The residue was taken up in EtOAc and washed with saturated aqueous sodium hydrogen carbonate solution, water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was taken up in aqueous NaOH solution (2 M, 175 mL, 350 mmol) and di-fe/f- butyl dicarbonate (17.65 g, 80.87 mmol) was added. The reaction mixture was stirred at RT overnight. The mixture was diluted with water and EtOAc. The layers were separated. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica, cyclohexane/EtOAc gradient, 0-10%) to afford INT 15 as a pale colorless oil.
MS (ESI): [M+H]+ 298.3. 1 H NMR (DMSO-d6): δ (ppm) 7.41-7.24 (m, 5H), 4.59-4.39 (m, 4H), 3.59-3.45 (m, 4H), 3.44-3.36 (m, 2H), 1.46-1 .31 (m, 9H).
(2) /V-Boc-/V-(2-fluoroethyl)-2-hydroxyethylamine, INT 16
Figure imgf000050_0001
To a solution of INT 15 (3.40 g, 1 1 .43 mmol) in THF (1 15 mL) was added Pd-C 10% (340 mg). The reaction mixture was hydrogenated at RT and normal pressure for 7 hr. Pd-C 10% (340 mg) was added, and the reaction mixture was hydrogenated at RT and normal pressure overnight. More Pd-C 10% (340 mg) was added, and the reaction mixture was hydrogenated at RT and normal pressure for an additional 4 hr. The mixture was diluted with DCM, filtered over a pad of Celite and concentrated to afford crude INT 16 as a colorless oil.
MS (ESI): [M+H]+ 208.2. 1 H NMR (DMSO-d6): δ (ppm) 4.70-4.63 (m, 1 H), 4.54 (t, 1 H), 4.42 (t, 1 H), 3.53 (t, 1 H), 3.46 (t, 3H), 3.28-3.21 (m, 2H), 1.39 (s, 9H).
(3) /V-(3-(6-Amino-5-(2-(/V-(2-fluoroethyl)acrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro- 2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 16 in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 540.3, rt = 0.96 min.
Example 16
/V-(3-(5-((1 -Aci^lamidocvclopropyl)methoxy)-6-aminop ^
methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000051_0001
-Boc-1 -(hydroxymethyl)-cyclopropylamine, INT 17
Figure imgf000051_0002
To a solution of methyl 1 -((fe/f-butoxycarbonyl)amino)cyclopropanecarboxylate (9.30 g, 43.20 mmol) in THF (45 mL) was added lithium borohydride solution (2 M in THF, 40.0 ml_, 80.00 mmol). The reaction mixture was stirred at RT overnight. The mixture was cooled to 0 °C and quenched carefully with water. The mixture was extracted with diethyl ether (2x). The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and concentrated to afford crude INT 17 as a white solid. MS (ESI): [M+H]+ 188.2. 1 H NMR (DMSO-d6): δ (ppm) 7.03 (s, 1 H), 4.55 (t, 1 H), 3.38 (d, 2H), 1 .37 (s, 9H), 0.63-0.50 (m, 4H).
(2) N-(3-(5-((1 -Acrylamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 17 in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 520.4, rt = 0.95 min. Example 17
(S)-/V-(3-(5-(2-Aci^lamidopropoxy)-6-amino
cyclopropyl-2-fluorobenzamide
Figure imgf000052_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with (S)-2- (Boc-amino)-l -propanol in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 508.2, rt = 0.95 min.
Example 18
(S)-/V-(3-(6-Amino-5-(2-(but-2-vnamido)propoxy)pyrirnidin-4-yl')-5-fluoro-2-rnethylphenyl')-
4-cvclopropyl-2-fluorobenzamide
Figure imgf000052_0002
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with (S)-2- (Boc-amino)-l -propanol in step 1 , and replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 520.2, rt = 0.97 min. Example 19
(S)-/V-(3-(6-Amino-5-(2-(/V-methylaci^lamido)propoxy)pyrimidin-4-yl
methylphenyl -cvclopropyl-2-fluorobenzamide
Figure imgf000053_0001
(1 ) (S)-/V-(3-(6-Amino-5-(2-aminopropoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4 amide, INT 18
Figure imgf000053_0002
INT 18 was prepared according to Scheme 2 following a procedure analogous to INT 10 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with (S)-2-(Boc-amino)-1 -propanol in step 1 , and replacing TFA with HCI in step 3 to afford INT 18 as the hydrochloride salt. UPLC-MS: MS (ESI): [M+H]+ 454.3, rt = 0.73 min.
(2) (S)-/V-(3-(6-Amino-5-(2-(benzyl(methyl)amino)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide, INT 19
Figure imgf000054_0001
To a solution of INT 18 (containing 2 eq of HCI, 590 mg, 1.12 mmol) in MeOH (30 mL) was added DIPEA (0.489 mL, 2.80 mmol), followed by acetic acid (0.321 mL, 5.60 mmol). Then a solution of benzaldehyde (131 mg, 1 .23 mmol) in MeOH (3 mL) was added. The mixture was stirred at RT for 1 h, then sodium cyanoborohydride (77 mg, 1.23 mmol) was added. The reaction mixture was stirred at RT for 1 h. More sodium cyanoborohydride (35 mg, 0.561 mmol) was added and the mixture was stirred for an additional hour. Formaldehyde (37% in water, 1 .00 mL, 13.45 mmol) was added, and stirring was continued for another hour. The mixture was diluted with DCM and washed with saturated aqueous sodium hydrogen carbonate solution. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-100%) to afford INT 19 as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 558.4, rt = 0.90 min. 1 H NMR (DMSO-d6): δ (ppm) 9.79 (s, 1 H), 8.20 (s, 1 H), 7.63 (t, 1 H), 7.55 (d, 1 H), 7.34-7.14 (m, 7H), 7.12-6.95 (m, 3H), 3.65- 3.56 (m, 1 H), 3.48 (d, 1 H), 3.39 (d, 1 H), 3.34-3.27 (m, 2H), 2.99-2.86 (m, 1 H), 2.03-1 .99 (m, 4H), 1 .94 (s, 3H), 1.1 1 -0.99 (m, 2H), 0.83-0.70 (m, 2H).
(3) (S)-/V-(3-(6-Amino-5-(2-(methylamino)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide, INT 20
Figure imgf000054_0002
To a solution of INT 19 (470 mg, 0.843 mmol) in MeOH (9 mL) was added Pd-C 10% (47 mg). The reaction mixture was hydrogenated at RT and normal pressure for 18 hr. More Pd-C 10% (47 mg) was added and the reaction was hydrogenated at RT and normal pressure overnight. The mixture was diluted with DCM and filtered over a pad of Celite. The filtrate was concentrated and the residue was dried in vacuum to afford crude INT 20 as brown-gray solid.
UPLC-MS: MS (ESI): [M+H]+ 468.4, rt = 0.76 min. 1 H NMR (DMSO-d6): δ (ppm) 9.84 (s, 1 H), 8.18 (s, 1 H), 7.65 (t, 1 H), 7.58-7.49 (m, 1 H), 7.28 (s, br, 1 H), 7.09-7.00 (m, 3H), 3.34-3.25 (m, 3H), 3.17 (s, br, 1 H), 2.17-1 .98 (m, 7H), 1.67 (s, br, 1 H), 1 .08-1 .01 (m, 2H), 0.81 -0.77 (m, 2H).
(4) (S)-/V-(3-(6-Amino-5-(2-(/ /-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to step 4 of Example 6 replacing INT 10 with INT 20.
UPLC-MS: MS (ESI): [M+H]+ 522.3, rt = 0.99 min.
Example 20
(5) -/V-(3-(6-Amino-5-(2-(/ /-methylbut-2-vnamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000055_0001
(1 ) (S)-ferf-Butyl (5-(2-(but-2-ynamido)propoxy)-6-(3-(/V-(fe/f-butoxycarbonyl)-4- cyclopropylbenzamido)-5-fluoro-2-methylphenyl)pyrimidin-4-yl)(fe/ - butoxycarbonyl)carbamate, INT 21
Figure imgf000056_0001
To a solution of Example 18 (152 mg, 0.29 mmol) in THF (10 mL) was added DIPEA (0.200 mL, 1 .15 mmol) followed by di-fe/f-butyl dicarbonate (233 mg, 1 .07 mmol) and 4-(dimethylamino)pyridine (4 mg, 0.033 mmol). The reaction mixture was stirred at RT overnight. More di-fe/f-butyl dicarbonate (100 mg, 0.46 mmol) was added and the reaction mixture was stirred at RT for 1 .5 hr. The mixture was concentrated under reduced pressure. The residue was purified by flash chromatography (silica;
cyclohexane/EtOAc gradient, 0-100%) to afford INT 21 as a yellow residue.
UPLC-MS: MS (ESI): [M+H]+ 820.4, rt = 1.48 min.
(2) (S)-fe/f-butyl fe/f-butoxycarbonyl(6-(3-(/V-(fe/ -butoxycarbonyl)-4-cyclopropyl- benzamido)-5-fluoro-2-methylphenyl)-5-(2-(/ /-methylbut-2-ynamido)propoxy)pyrimidin-4-
Figure imgf000056_0002
To a solution of INT 21 (257 mg, 0.31 mmol) and iodomethane (0.040 mL, 0.64 mmol) in DMF (5.0 mL) at 0 °C was added NaH (60% in mineral oil, 26 mg, 0.65 mmol). The reaction mixture was stirred for 1 .5 hr while allowing to warm to RT. The mixture was poured into aqueous HCI (0.5 M) and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0- 100%) to afford INT 22.
UPLC-MS: MS (ESI): [M+H]+ 834.5, rt = 1.49 min.
(3) (S)-/V-(3-(6-Amino-5-(2-(/ /-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro- 2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
To a solution of INT 22 (1 17 mg, 0.14 mmol) in DCM (5.0 mL) was added TFA (0.200 ml_, 2.60 mmol) followed by one drop of water. The reaction mixture was stirred at RT overnight. The mixture was concentrated. The residue was taken up in EtOAc and washed with saturated aqueous sodium hydrogen carbonate solution. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; EtOAc/MeOH gradient, 0-15%) followed by purification by SFC to afford Example 20.
UPLC-MS: MS (ESI): [M+H]+ 534.3, rt = 1.02 min. . 1 H NMR (CDCI3): δ (ppm) rotamers 8.65-8.54 (m, 1 H), 8.38 and 8.33 (s, total 1 H), 8.19-8.05 (m, 2H), 7.07-6.95 (m, 2H), 6.90-6.82 (m, 1 H), 5.76 and 5.23 (s, total 2H), 4.99-4.92 and 4.76-4.68 (m, total 1 H), 3.54-3.45 (m, 1 H), 3.43-3.37 and 3.28-3.21 (m, total 1 H), 2.91 and 2.65 (s, total 3H), 2.16 (s, 3H), 2.03-1 .92 (overlapping s and m, total 4H), 1 .15-1.08 (m, 2H), 1 .01 and 0.95 (d, total 3H), 0.83-0.77 (m, 2H).
Example 21
/V-(3-(6-Amino-5-(3-(/V-methylaci^lamido)propoxy)p^
methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000058_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with N-Boc-N- methyl-3-hydroxypropylamine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 522.4, rt = 0.95 min.
Example 22
Figure imgf000058_0002
meth lphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000058_0003
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with (S)-N- Boc-2-(hydroxymethyl)pyrrolidine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 534.3, rt = 1 .00 min. Example 23
(S)-/V-(3-(6-Amino-5-(n-(but-2-vnovnpyrro^
methylphenyl -cvclopropyl-2-fluorobenzamide
Figure imgf000059_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with (S)-N- Boc-2-(hydroxymethyl)pyrrolidine in step 1 , and replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 546.3, rt = 1 .02 min.
Example 24
Figure imgf000059_0002
(hydroxymethyl')phenyl')-6-cvclopropyl-3,4-dihvdroisoquinolin-1 (2 - )-one
Figure imgf000059_0003
(1 ) 2-(6-Cyclopropyl-1 -oxo-3, 4-dihydroisoquinolin-2(1 H)-yl)-4-fluoro-6-(4, 4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzyl acetate, INT 23
Figure imgf000060_0001
INT 23 was prepared following a procedure analogous to INT 2 replacing 1 -bromo-5- fluoro-2-methyl-3-nitro-benzene with acetic acid 2-bromo-6-(6-cyclopropyl-1 -oxo-3,4- dihydro-1 H-isoquinolin-2-yl)-benzyl ester (WO2010/000633).
UPLC-MS: MS (ESI): [M+H]+ 480.4, rt = 1.36 min. 1 H NMR (DMSO-d6): δ (ppm) 7.76 (s, 1 H), 7.49-7.46 (m, 1 H), 7.38-7.35 (m, 1 H), 7.10 (d, 1 H), 7.06 (s, 1 H), 5.24 (d, 1 H), 4.93 (d, 1 H), 4.07-3.98 (m, 1 H), 3.65-3.58 (m, 1 H), 3.15-2.99 (m, 2H), 2.04-1.96 (m, 1 H), 1 .91 (s, 3H), 1 .31 (s, 12H), 1 .05-1.00 (m, 2H), 0.80-0.75 (m, 2H).
(2) (S)-fe/f-Butyl 2-(((4-amino-6-chloropyrimidin-5-yl)oxy)methyl)pyrrolidine-1-
Figure imgf000060_0002
INT 24 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with (S)-/V-Boc-2-
(hydroxymethyl)pyrrolidine.
UPLC-MS: MS (ESI): [M+H]+ 329.2, rt = 0.97 min.
(3) (S tert- Butyl 2-(((4-amino-6-(3-(6-cyclopropyl-1 -oxo-3,4-dihydroisoquinolin- 2(1 H)-yl)-5-fluoro-2-(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)methyl)pyrrolidine-1 - carboxylate, INT 25
Figure imgf000061_0001
To a solution of INT 24 (content 66%, 200 mg, 0.40 mmol) in DME (3.0 mL) and water (0.43 mL) was added INT 23 (212 mg, 0.44 mmol) followed by aqueous sodium carbonate solution (1 M, 1 .20 mL, 1.20 mmol). The mixture was degassed with argon for 10 min, then bis(triphenylphosphine)-palladium(ll) dichloride (14 mg, 0.020 mmol) was added. The reaction mixture was stirred at 90 °C for 6 hr. After cooling to RT, aqueous NaOH solution (2 M, 2.0 mL, 4.00 mmol) was added and the mixture was stirred at RT for 20 min. The mixture was diluted with saturated aqueous sodium hydrogen carbonate solution and extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-100%) to afford INT 25 as a beige solid.
UPLC-MS: MS (ESI): [M+H]+ 604.5, rt = 1.20 min. 1 H NMR (DMSO-d6): δ (ppm) 8.21 (s, 1 H), 7.79 (d, 1 H), 7.40 (d, 1 H), 7.21 (d, 1 H), 7.1 1 (d, 1 H), 7.07 (s, 1 H), 7.04-6.87 (s, br, 2H), 4.86-4.66 (m, 1 H), 4.31 (m, 2H), 4.03-3.93 (m, 1 H), 3.81 -3.70 (m, 2H), 3.64-3.53 (m, 2H), 3.35-3.00 (m, 4H), 2.03-1 .97 (m, 1 H), 1.64-1 .44 (m, 4H), 1.40-1 .24 (m, 9H), 1.06-1 .01 (m, 2H), 0.79-0.76 (m, 2H).
(4) (S)-2-(3-(6-Amino-5-(pyrrolidin-2-ylmethoxy)pyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2H)-one, INT 26
Figure imgf000062_0001
INT 26 was prepared according to Scheme 2 following a procedure analogous to step 3 of Example 6 replacing INT 9 with INT 25.
UPLC-MS: MS (ESI): [M+H]+ 504.4, rt = 0.75 min.
(5) (S)-2-(3-(5-((1 -Aci loylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one
The title compound was prepared according to Scheme 2 following a procedure analogous to step 4 of Example 6 replacing INT 10 with INT 26.
UPLC-MS: MS (ESI): [M+H]+ 558.4, rt = 0.98 min.
Example 25
/V-(2-((4-Amino-6-(3-(6-cvclopropyl-1 -oxo-3,4-dihydroisoquinolin-2(1 - )-yl)-5-fluoro-2-
(hvdroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methylacrylamide
Figure imgf000062_0002
(1 ) 2-(3-(6-Amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)-phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2H)-one, INT 27
Figure imgf000063_0001
INT 27 was prepared according to Scheme 2 following a procedure analogous to INT 26 replacing INT 24 with INT 8 in step 3, and purifying the TFA salt over a SPE cartridge (PL-HC03 MP resin) to afford INT 27 as the free amine in step 4.
UPLC-MS: MS (ESI): [M+H]+ 478.3, rt = 0.62 min.
(2) A/-(2-((4-Amino-6-(3-(6-cyclopropyl-1 -oxo-3,4-dihydroisoquinolin-2(1 H)-y\)-5- fluoro-2-(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methylacrylamide
To a solution of INT 27 (free amine, 130 mg, 0.272 mmol) and DIPEA (0.238 ml, 1 .361 mmol) in DCM (9.0 mL) at -20 °C was added a solution of acryloyl chloride (24.64 mg, 0.272 mmol) in DCM (0.6 mL). The reaction mixture was stirred at -20 °C for 10 min. The mixture was diluted with DCM and poured into brine. The aqueous layer was back- extracted with DCM. The combined organic layers were dried over sodium sulfate and filtered. The filtrate was directly loaded onto a silica cartridge and purified by flash chromatography (silica; heptane/acetone gradient, 0-80%) to afford a white solid. The residue was triturated in acetonitrile, filtered off, and rinsed with acetonitrile. The solid was dried in vacuum to afford Example 25 as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 530.5, rt = 0.89 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 8.23-8.16 (m, 1 H), 7.83-7.77 (m, 1 H), 7.43-7.32 (m, 1 H), 7.20-7.04 (m, 5H), 6.70-6.60 (m, 1 H), 6.1 1 -6.00 (m, 1 H), 5.69-5.53 (m, 1 H), 4.77-4.61 (m, 1 H), 4.37-4.24 (m, 2H), 4.05-3.93 (m, 1 H), 3.83-3.73 (m, 1 H), 3.68-3.55 (m, 2H), 3.54-3.44 (m, 1 H), 3.27-3.15 (m, 2H), 3.09-2.99 (m, 1 H), 2.89-2.55 (m, 3H), 2.05-1 .95 (m, 1 H), 1 .08-0.99 (m, 2H), 0.81 -0.74 (m, 2H). Example 26
/V-(3-(5-(((2S,4/?)-1 -Aci^loyl-4-methoxypyrrolidin^
fluoro-2-methylphenyl -cyclopropyl-2-fluorobenzamide
methoxypyrrolidine-2-carboxylic acid, INT 28
Figure imgf000064_0001
INT 28 was prepared following a procedure analogous to WO2002/102790.
MS (ESI): [M-H]" 244.2. 1 H NMR (DMSO-d6): δ (ppm) rotamers 4.05-3.97 (m, 1 H), 3.95- 3.87 (m, 1 H), 3.45-3.30 (m, 2H), 3.20 (s, 3H), 2.25-2.1 1 (m, 1 H), 1.99-1 .91 (m, 1 H), 1 .39 and 1 .33 (s, total 9H). Boc-2-(hydroxymethyl)-4-methoxypyrrolidine, INT 29
Figure imgf000064_0002
To solution of INT 28 (5.00 g, 20.39 mmol) in THF (100 mL) at 0 °C was added borane tetrahydrofuran complex solution (1 M in THF, 30.6 mL, 30.6 mmol) dropwise. The reaction mixture was stirred at RT for 6 hr. The mixture was cooled to 0 °C and water (80 mL) was added dropwise. The resulting mixture was stirred at 0 °C for 1 hr, then diluted with EtOAc. The organic layer was washed with aqueous 10% citric acid solution, saturated aqueous sodium hydrogen carbonate solution and brine, dried over magnesium sulfate, filtered and concentrated. The residue was dried in vacuum to afford crude INT 29 as a colorless liquid.
MS (ESI): [M+H-tBuf 176.1 . 1 H NMR (DMSO-d6): δ (ppm) 4.69 (t, 1 H), 3.94-3.88 (m, 1 H), 3.73 (s, v br, 1 H), 3.48-3.36 (m, 3H), 3.31-3.22 (m, 1 H), 3.20 (s, 3H), 2.08-1.87 (m, 2H), 1 .40 (s, 9H).
(3) (2S,4f?)-fe/f-Butyl 2-(((4-amino-6-chloropyrimidin-5-yl)oxy)methyl)-4- methoxypyrrolidine-1 -carboxylate, INT 30
Figure imgf000065_0001
INT 30 was prepared according to Scheme 2 following a procedure analogous to of Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 29.
UPLC-MS: MS (ESI): [M+H]+ 359.3, rt = 0.91 min.
(4) A/-(3-(5-(((2S,4f?)-1 -Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6- aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing INT 8 with INT 30 in step 2.
UPLC-MS: MS (ESI): [M+H]+ 564.4, rt = 0.98 min.
Example 27
/V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-vnoyl)-4-methoxypyrro^^
yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000066_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with INT 29 in step 1 , and replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 576.4, rt = 1.01 min.
Example 28
2-(3-(5-(((2S,4/?)-1 -Aci^loyl-4-methoxypyrrolidin-2-vnmethoxy)-6-aminopyrirnidin-4-yl')-5- fluoro-2-(hvdroxymethyl')phenyl')-6-cvclopropyl-3,4-dihvdroisoquinolin-1 (2 - )-one
Figure imgf000066_0002
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 24 replacing INT 24 with INT 30 in step 3.
UPLC-MS: MS (ESI): [M+H]+ 588.5, rt = 0.95 min. Example 29
/V-(3-(5-(((2S,4S)-1 -Aci^loyl-4-methoxypyrrolidin-2-vn^
fluoro-2-methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000067_0001
(1 ) (2S,4S)-Methyl A/-Boc-4-methoxypyrrolidine-2-carboxylate, INT 31
Figure imgf000067_0002
To a solution of (2S,4S)-methyl A/-Boc-4-hydroxypyrrolidine-2-carboxylate (3.00 g, 12.23 mmol) in acetonitrile (60 mL) was added silver oxide (2.83 g, 12.23 mmol) followed by iodomethane (15.0 mL, 240.95 mmol). The reaction mixture was stirred at 85 °C for 4 hr. More iodomethane (5.0 mL, 80.32 mmol) was added and the mixture was stirred at 85 °C for an additional 5 hr. The mixture was filtered over a pad of Celite. The filtrated was diluted with diethyl ether and washed with saturated aqueous sodium hydrogen carbonate solution. The aqueous layer was back-extracted with diethyl ether. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to afford crude INT 31 as a pale yellow oil.
MS (ESI): [M+H]+ 260.3. 1 H NMR (DMSO-d6): δ (ppm) rotamers 4.30-4.23 (m, 1 H), 3.95- 3.91 (m, 1 H), 3.64 and 3.61 (s, total 3H), 3.55-3.50 (m, 1 H), 3.27-3.21 (m, 1 H), 3.17 and 3.16 (s, total 3H), 2.42-2.28 (m, 1 H), 2.06-1 .97 (m, 1 H), 1 .41 and1 .34 (s, total 9H).
(2S,4S)-N-Boc-2-(hydroxymethyl)-4-methoxypyrrolidine, INT 32
Figure imgf000068_0001
To a solution of INT 31 (3.10 g, 1 1 .96 mmol) in THF (120 mL) at 0 °C was added lithium borohydride solution (2 M in THF, 1 1.96 mL, 23.91 mmol). The reaction mixture was stirred at RT overnight. The mixture was cooled to 0 °C and poured onto ice water. The mixture was stirred for 15 min at RT, then extracted with diethyl ether. The aqueous layer was back-extracted with diethyl ether. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to afford crude INT 32 as a colorless oil.
MS (ESI): [M+H]+ 232.3. 1 H NMR (DMSO-d6): δ (ppm) 4.64 (t, 1 H), 3.87 (s, 1 H), 3.68- 3.44 (m, 3H), 3.32-3.26 (m, 1 H), 3.21 (s, 3H), 3.18-3.15 (m, 1 H), 2.04-1 .97 (m, 1 H), 1.42-1 .34 (m, 1 H), 1 .40 (s, 9H).
(3) A/-(3-(5-(((2S,4S)-1 -Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6- aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 32 in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 564.4, rt = 0.99 min.
Example 30
/V-(3-(6-Amino-5-(((2S^S)-1-(but-2-vnovn-4-methoxypyrrolidin-2-vnmethoxy)py vn-5-fluoro-2-methylphenyl -cyclopropyl-2-fluorobenzamide
Figure imgf000069_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with INT 32 in step 1 , and replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 576.4, rt = 1.02 min.
Example 31
/V-(3-(5-(((2S,4/?)-1-Aci^loyl-4-fluoropyrro^
fluoro-2-methylphenyl -cyclopropyl-2-fluorobenzamide
Figure imgf000069_0002
(1 ) (2S,4f?)-/V-Boc-4-fluoropyrrolidine-2-carboxylic acid, INT 33
Figure imgf000070_0001
A solution of (2S,AR) methyl A/-Boc-4-hydroxypyrrolidine-2-carboxylate (250 g, 1 .02 mol), triphenylphosphine (401 g, 1 .53 mmol) and benzoic acid (187 g, 1 .53 mol) in TH F (3.50 L) was cooled to reach an internal temperature of -4 °C, then a diethyl
azodicarboxylate solution (40% in toluene, 625 ml_, 1 .43 mmol) in THF (1 .50 L) was added within 1 hr. The reaction mixture was warmed to RT and stirred at RT overnight. The mixture was concentrated. The residue was taken up in diethyl ether (2.5 L) and the mixture was refluxed for 1 hr. The suspension was cooled to 0 °C, the white solid was filtered off, and washed with cold ethanol. The filtrate was concentrated. The residue was dissolved in a 4: 1 mixture of warm hexane/EtOAc (1 .5 L) and stirred at RT for 1 hr. The mixture was cooled to 10 °C and treated with hexane (250 ml_). The mixture was stirred at RT for 30 min and a precipitate was formed. The solid was filtered off and washed with cold hexane (150 ml_). The filtrate was concentrated. The residue was purified by flash chromatography (silica; hexane/EtOAc 4: 1 ) to afford (2S,4S)-2-methyl A/-Boc-4-(benzoyloxy)pyrrolidine-2-carboxylate as a white solid.
To a solution of (2S,4S)-2-methyl A/-Boc-4-(benzoyloxy)pyrrolidine-2-carboxylate (248 g, 0.71 mol) in MeOH (4.5 L) was added sodium carbonate (98 g, 0.92 mol) followed by more MeOH (0.5 L). The reaction mixture was stirred at RT for 4 hr. The mixture was filtered, and the filtrated was concentrated to a volume of approximately 1 L. The solution was diluted with EtOAc (5.0 L), cooled to 5 °C and washed with water. The aqueous layer was back-extracted with EtOAc (2x). The combined organic layers were washed with brine and a 1 : 1 mixture of brine and water, dried over sodium sulfate, filtered and concentrated. The residue was crystallized from DCM/hexane to afford (2S,4S)-2-methyl A/-Boc-4-hydroxy-pyrrolidine-2-carboxylate as a white solid.
To a solution of (2S,4S)-2-methyl A/-Boc-4-hydroxy-pyrrolidine-2-carboxylate (270 g, 1 .10 mol) in DCM (2.6 L) at -80 °C was added (diethylamino)sulfur trifluoride (567 ml_, 4.29 mol) dropwise. The reaction mixture was stirred at RT overnight. The mixture was cooled to -78 °C and then added to a saturated aquous sodium hydrogen carbonate solution cooled to -10 °C. During the addition the inner temperature was kept below 5 °C. The mixture was then stirred at 0 °C for 30 min. The layers were separted, the aqueous layer was back-extracted with DCM. The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate solution, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; hexane/EtOAc gradient, 10-40%) to afford (2S,4f?)-2-methyl A/-Boc-4-fluoro- pyrrolidine-2-carboxylate as a yellow oil.
To a solution of (2S,4f?)-2-methyl A/-Boc-4-fluoro-pyrrolidine-2-carboxylate (13.0 g, 52.58 mmol) in dioxane (270 mL) at 15 °C was added a solution of sodium hydroxide (4.2 g, 105.00 mmol) in water (30 mL) dropwise. The mixture was cooled to 7 °C and the slurry was stirred at 7 °C overnight. Acetic acid (80 mL) was added and the mixture was diluted with DCM. The layers were separated, the aqueous layer was back-extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was crystallized from diethyl ether/hexane to afford INT 33 as a white solid.
MS (ESI): [M-H]- 232.2. 1 H NMR (DMSO-d6): δ (ppm) rotamers 12.72 (s, br, 1 H), 5.40- 5.21 (m, 1 H), 4.22-4.13 (m, 1 H), 3.72-3.58 (m, 1 H), 3.58-3.36 (m, 1 H), 2.60-2.44 (m, 1 H, overlapping with solvent peak), 2.19-1 .97 (m, 1 H), 1.41 and 1 .36 (s, total 9 H).
(2) (2S,4f?)-N-Boc-2-(hydroxymethyl)-4-fluoropyrrolidine, INT 34
Figure imgf000071_0001
To a solution of INT 33 (5.00 g, 21 .44 mmol) in THF (105 mL) at 0 °C was added borane tetrahydrofuran complex solution (1 M in THF, 32.2 mL, 32.20 mmol). The reaction mixture was stirred at RT for 3 hr. The mixture was cooled to 0 °C and water (100 mL) was added dropwise. The resulting mixture was stirred at 0 °C for 1 hr, then extracted with EtOAc. The organic layer was washed with aqueous 10% citric acid solution, saturated aqueous sodium hydrogen carbonate solution and brine, dried over magnesium sulfate, filtered and concentrated to afford crude INT 34 as a yellow oil. MS (ESI): [M+H-tBuf 164.2. 1 H NMR (DMSO-d6): δ (ppm) 5.23 (d, 1 H), 4.74 (t, 1 H), 3.84 (m, 1 H), 3.74-3.62 (m, 1 H), 3.57-3.44 (m, 2H), 3.41 -3.23 (m, 1 H), 2.22-2.05 (m, 2H), 1 .41 (s, 9H). (3) /V-(3-(5-(((2S,4/?)-1 -Aci loyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrim yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing /V-Boc-/V-methyl-2-hydroxyethylamine with INT 34 in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 552.5, rt = 1.00 min.
Example 32
/V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-vnoyl -fluoropyrrolidin-2-vnmethoxy)pyrirnidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000072_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 34 in step 1 , and replacing acrylic acid with 2-butynoic acid in step 4.
UPLC-MS: MS (ESI): [M+H]+ 564.5, rt = 1.03 min.
Example 33
(S)-/V-(3-(5-((1 -Aci^loylazetidin-2^l)methoxy)-6-am
methylphenyl)-4-cyclopropyl-2-fluorobenzamide
oxymethyl)azetidine, INT 35
Figure imgf000073_0001
INT 35 was prepared according to Scheme 2 following a procedure analogous to step 2 of Example 26 replacing INT 28 with (S)-/V-Boc-azetidine-2-carboxylic acid.
MS (ESI): [M+H]+ 188.1 .
(2) (S)-/V-(3-(5-((1 -Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 35 in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 520.2, rt = 0.96 min.
Example 34
(^)-/V-(3-(B-Amino-5-(Y1 -propioloylazetidin-2-vnm
methylphenyl -cvclopropyl-2-fluorobenzamide
Figure imgf000074_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-2-hydroxyethylamine with INT 35 in step 1 , and replacing acrylic acid with propiolic acid in step 4.
UPLC-MS (ESI): [M+H]+ 518.3, rt = 0.96 min.
Example 35
(S'l^-f^S-i^S-^l -Acr loylazetidin^-vnmethoxy'l-e-aminopyrimidin^-vn-S-fluoro^- (hydroxymethyl')phenyl')-6-cvclopropyl-3,4-dihvdroisoquinolin-1 (2 - )-one
Figure imgf000074_0002
(1 ) (S)-fe/f-Butyl 2-(((4-amino-6-chloropyrimidin-5-yl)oxy)methyl)azetidine-1 - carboxylate, INT 36
Figure imgf000074_0003
INT 36 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing A/-Boc-/V-methyl-hydroxyethylamine with INT 35.
UPLC-MS: MS (ESI): [M+H]+ 315.1 , rt = 0.91 min.
(2) (S)-2-(3-(5-((1 -Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 24 replacing INT 24 with INT 36 in step 3.
UPLC-MS: MS (ESI): [M+H]+ 544.4, rt = 0.94 min.
Example 36
(/?)-/V-(3-(5-((1 -Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000075_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 33 replacing (S)-/V-Boc-azetidine-2-carboxylic acid with (R)-N- Boc-azetidine-2-carboxylic acid in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 520.3, rt = 0.99 min. Example 37
(/?)-/V-(3-(5-(n-Aci^loylpiperidin-3-vnmethoxy)-6-aminopyrimidin-4^^
methylphenyl -cvclopropyl^-fluorobenzamide
Figure imgf000076_0001
The title compound was prepared according to Scheme 2 following a procedure analogous to Example 6 replacing A/-Boc-/V-methyl-hydroxyethylamine with (R)-N-Boc- 3-(hydroxylmethyl)piperidine in step 1 .
UPLC-MS: MS (ESI): [M+H]+ 548.5, rt = 1 .02 min.
Alternatively, agents of the invention may be prepared by a reaction sequence involving deprotection e.g. with a Lewis acid of 4,6-dichloro-5-methoxypyrimidine 8 to yield 4,6- dichloro-5-hydroxyoxy-pyrimidine 9, followed by a Mitsunobu reaction of the pyrimidinol with an alcohol compound 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine to yield intermediate 10, followed by a nucleophilic aromatic substitution e.g. with ammonia in water to yield the aminopyrimidine intermediate 3. Thereupon intermediate 3 is converted into a final compound of the invention, i.e. a compound 7, by the earlier described reaction sequences of scheme 1 and/or scheme 2, i.e. a Suzuki coupling with a boronic ester using an appropriate catalyst, such as bis(triphenylphosphine) palladium(l l) dichloride, deprotection using an appropriate acid, such as TFA or HCI, followed by amide formation e.g. of the ammonium salt or the free amine with an acid and using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or with an acid chloride using an appropriate base, such as DI PEA, as shown in Scheme 3 below: Scheme 3:
Figure imgf000077_0001
7
Example 38
/V-(3-(5-(((2 3S)-1 -Aci^loyl-3-methoxypyrrolidin-2-^
fluoro-2-methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000078_0001
(1 ) 4,6-Dichloropyrimidin-5-ol, INT 37
Figure imgf000078_0002
To a solution of 4,6-dichloro-5-methoxypyrimidine (5.00 g, 27.93 mmol) in DCE (80 mL) at 0 °C was added aluminum chloride (5.48 g, 41 .10 mmol) in one portion. The reaction mixture was stirred vigorously at 50 °C for 6 hr. The mixture was cooled to 0 °C and aqueous HCI solution (1 M, 40 mL) followed by MeOH (10 mL) were added slowly. The mixture was stirred vigorously at RT for 10 min, then diluted with water and extracted with a mixture of DCM/MeOH (10: 1 , 2 x 100 mL) and EtOAc (1 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to afford crude INT 37 as beige solid.
UPLC-MS: MS (ESI): [M-H]" 163.0, rt = 0.45 min. 1 H NMR (DMSO-d6): δ (ppm) 1 1.71 (s, br, 1 H), 8.39 (s, 1 H).
(2) (2S.3S) 2-Methyl A/-Boc-3-hydroxypyrrolidine-2-carboxylate, INT 38
Figure imgf000078_0003
To a solution of (2S,3S)-N-Boc-3-hydroxypyrrolidine-2-carboxylic acid (4.10 g, 17.73 mmol) in DMF (100 mL) at 0 °C was added potassium carbonate (4.00 g, 28.94 mmol) followed by iodomethane (1 .3 mL, 20.79 mmol). The reaction mixture was warmed to RT and stirred at RT for 4 hr, then at 90 °C for 1 hr. After cooling to RT iodomethane (0.70 mL, 1 1 .19 mmol) was added and the reaction mixture was stirred at RT overnight. The mixture was diluted with brine and extracted with EtOAc (3x). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-50%) to afford INT 38 as a colorless oil.
MS (ESI): [M+H]+ 246.2. 1 H NMR (CDCI3): δ (ppm) rota me rs 4.42 (s, br, 1 H), 4.29 and 4.18 (s, total 1 H), 3.74 (s, 3H), 3.66-3.53 (m, 3H), 2.13-2.03 (m, 1 H), 1 .97-1.88 (m, 1 H), 1.46 and 1 .41 (s, total 9H). ethyl A/-Boc-3-methoxypyrrolidine-2-carboxylate, INT 39
Figure imgf000079_0001
To a solution of INT 38 (2.53 g, 10.33 mmol) in DMF (25.0 mL) was added iodomethane (3.2 mL, 51 .60 mmol) followed by silver(l) oxide (7.18 g, 31 .00 mmol). The reaction mixture was stirred at RT over the weekend. The mixture was diluted with EtOAc and filtered through a pad of Celite. The filtrate was washed with brine, aqueous 10% sodium thiosulfate solution and saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over sodium sulfate, filtered and concentrated to afford crude INT 39 as a colorless oil.
1H NMR (CDCI3): δ (ppm) rotamers 4.41 and 4.26 (s, total 1 H), 3.94-3.87 (m, br, 1 H), 3.75 (s, 3H), 3.69-3.53 (m, 2H), 3.38 (s, 3H), 2.1 1 -1.95 (m, 2H), 1 .46 and 1 .41 (s, total 9H).
(2ft,3S)-/V-Boc-2-hydroxymethyl-3-methoxy-pyrrolidine, INT 40
Figure imgf000080_0001
To a solution of INT 39 (2.28 g, 8.81 mmol) in THF (25 mL) was added lithium chloride (1 .12 g, 26.40 mmol) followed by sodium borohydride (1 .00 g, 26.40 mmol). EtOH (50 mL) was added and the reaction mixture was stirred at RT for 4 hr. The mixture was cooled to 0 °C and water was added slowly. The mixture was extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and
concentrated. The aqueous layer diluted with saturated aqueous ammonium chloride solution and back-extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The combined residues were purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 15-100%) to afford INT 40 as a colorless liquid.
MS (ESI): [M+H]+ 232.2. 1 H NMR (CDCI3): δ (ppm) rotamers 4.03-3.92 and 3.89-3.77 (m, br, total 2H), 3.72-3.55 (m, br, 2H), 3.52-3.30 (overlapping m, 2H and s, 3H), 2.01 -1 .92 (m, br, 2H), 1 .47 (s, 9H).
(5) (2f?,3S)-fe/f-Butyl 2-(((4,6-dichloropyrimidin-5-yl)oxy)methyl)-3- methoxypyrrolidine-1 -carboxylate, INT 41
Figure imgf000080_0002
To a solution of INT 37 (105 mg, 0.64 mmol) and INT 40 (221 mg, 0.96 mmol) in THF (12 mL) was added triphenylphosphine (250 mg, 0.96 mmol) followed by the dropwise addition of DIAD (0.186 mL, 0.96 mmol). The reaction mixture was stirred at 60 °C overnight. The mixture was concentrated under reduced pressure. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-40%) to afford INT 41 as a colorless residue. UPLC-MS: MS (ESI): [M+H-tBu]+ 322.1 , rt = 1 .17 min. 1 H NMR (CDCI3): δ (ppm) rotamers 8.57 and 8.54 (s, total 1 H), 4.35-3.91 (m, 4H), 3.58-3.46 (m, 2H), 3.42 (s, 2.24-1 .97 (m, 2H), 1 .46 (s, 9H).
(6) (2f?,3S)-fe/f-Butyl 2-(((4-amino-6-chloropyrimidin-5-yl)oxy)methyl)-3- methoxypyrrolidine-1 -carboxylate, INT 42
Figure imgf000081_0001
To a solution of INT 41 (173 mg, 0.46 mmol) in 2-propanol (5.0 mL) was added aqueous 33% ammonium hydroxide solution (2.7 mL, 22.63 mmol). The reaction mixture was stirred in a sealed tube at 80 °C for 5 hr. The mixture was concentrated under reduced pressure. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-50%) to afford INT 42 as a colorless oil.
UPLC-MS: MS (ESI): [M+H]+ 359.2, rt = 0.92 min. 1 H NMR (CDCI3): δ (ppm) rotamers 8.08 (s, 1 H), 6.22 and 5.78 (s, br, total 2H), 4.25-3.95 (m, br, 4H), 3.61 -3.37 (m, 5H, including s, 3H, at δ 3.40), 2.18-1 .95 (m, 2H), 1.46 (s, 9H).
(7) A/-(3-(5-(((2f?,3S)-1 -Acryloyl-3-methoxypyrrolidin-2-yl)methoxy)-6- ro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, INT 43
Figure imgf000081_0002
INT 43 was prepared according to Scheme 3 following a procedure analogous to step 2 of Example 6 replacing INT 8 with INT 42.
UPLC-MS: MS (ESI): [M+H]+ 610.5, rt = 1.21 min. (8) /V-(3-(6-Amino-5-(((2/?,3S)-3-methoxypyrrolidin-2-yl)methoxy)pyrimidi
-cyclopropyl-2-fluorobenzamide, INT 44
Figure imgf000082_0001
INT 44 was prepared according to Scheme 3 following a procedure analogous to step 3 of Example 6 replacing INT 9 with INT 43 and purifying the crude by flash
chromatography (silica; DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 5-65%) to afford INT 44 as the free amine.
UPLC-MS: MS (ESI): [M+H]+ 510.3, rt = 0.77 min.
(9) A/-(3-(5-(((2f?,3S)-1 -Acryloyl-3-methoxypyrrolidin-2-yl)methoxy)-6- aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
The title compound was prepared according to Scheme 3 following a procedure analogous to step 4 of Example 6 replacing INT 10 with INT 44.
UPLC-MS: MS (ESI): [M+H]+ 564.3, rt = 0.98 min. 1 H NMR (CDCI3): δ (ppm) rotamers 8.60 and 8.55 (s, total 1 H), 8.42 and 8.36 (s, total 1 H), 8.20-8.13 (m, 1 H), 8.13-8.04 (m, 1 H), 7.07-7.01 (m, 1 H), 6.96-6.83 (m, 2H), 6.47-6.32 (m, 2H), 5.79 (s, v br, 2H), 5.72- 5.66 (m, 1 H), 4.21 -4.16 and 3.70-3.42 and 3.33-3.28 (m, total 6H), 3.26 and 3.20 (s, total 3H), 2.15 (s, 3H), 2.01-1 .88 (m, 2H), 1 .84-1 .74 (m, 1 H), 1 .16-1.07 (m, 2H), 0.84-0.75 (m, 2H). Alternatively, agents of the invention may be prepared by a reaction sequence involving alkylation of 4,6-dichloro-5-hydroxy-pyrimidine 9 with benzyl bromide using an appropriate base, such as potassium carbonate, followed by nucleophilic aromatic substitution with ammonium hydroxide to yield the aminopyrimidine 12, Suzuki coupling with a boronic ester 4 using an appropriate catalyst, such as bis(triphenylphosphine)- palladium(ll) dichloride to yield the benzylated intermediate 13. Cleavage of the benzyl group, e.g. by hydrogenation, followed by a Mitsunobu reaction of the pyrimidinol with an alcohol of formula 2' using an appropriate azodicarboxylate, such as DIAD, and
Smopex-301 or triphenylphosphine, deprotection using an appropriate acid, such as TFA or HCI, followed by amide formation of the ammonium salt or the free amine with an acid using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or with an acid chloride using an appropriate base, such as DIPEA, to yield a final compound of the invention, i.e. a compound of formula 7, as shown in Scheme 4 below:
Figure imgf000083_0001
13
Figure imgf000084_0001
Example 39
/V-(3-(5-(((2S,4/?)-1 -Aci^loyl-4-cvanopyrrolidin-2^
fluoro-2-methylphenyl)-4-cvclopropyl-2-fluorobenzamide
Figure imgf000085_0001
-(Benzyloxy)-4,6-dichloropyrimidine, INT 45
Figure imgf000085_0002
To a solution of INT 37 (content 90%, 6.50 g, 35.50 mmol) in DMF (120 mL) was added benzyl bromide (8.42 mL, 70.90 mmol) followed by potassium carbonate (14.70 g, 106.36 mmol). The reaction mixture was stirred at 60 °C for 1 hr. The mixture was concentrated. The residue was partitioned between EtOAc and water. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and
concentrated. The residue was purified by flash chromatography (silica;
cyclohexane/ EtOAc gradient, 0-10%) to afford INT 45 as a colorless oil.
UPLC-MS: MS (ESI): [M+H]+ 255.1 , rt = 1.15 min. 1 H NMR (DMSO-d6): δ (ppm) 8.72 (s, 1 H), 7.57-7.50 (m, 2H), 7.48-7.37 (m, 3H), 5.19 (s, 2H). -(Benzyloxy)-6-chloropyrimidin-4-amine, INT 46
Figure imgf000085_0003
To a solution of INT 45 (8.24 g, 32.30 mmol) in 2-propanol (100 mL) was added aqueous 26% ammonium hydroxide solution (93 mL, 614 mmol) in an autoclave. The reaction mixture was stirred at 80 °C for 12 hr. The mixture was concentrated. The residue was partitioned between EtOAc and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to afford crude INT 46 as a white solid.
UPLC-MS: MS (ESI): [M+H]+ 236.1 , rt = 0.84 min. 1 H NMR (DMSO-d6): δ (ppm) 7.98 (s, 1 H), 7.58-7.51 (m, 2H), 7.43-7.32 (m, 3H), 7.25 (s, br, 2H), 4.95 (s, 2H).
(3) A/-(3-(6-Amino-5-(benzyloxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- amide, INT 47
Figure imgf000086_0001
To a solution of INT 46 (content 90%, 500 mg, 1 .91 mmol) in DME (7.0 mL) and water (1 .0 mL) was added INT 5 (947 mg, 2.29 mmol) followed by aqueous sodium carbonate solution (2 M, 2.86 mL, 5.73 mmol). The mixture was degassed with argon for 10 min, then. bis(triphenyl-phosphine)palladium(ll) dichloride (67.0 mg, 0.095 mmol) was added and the reaction mixture was stirred at 120 °C for 15 min in a microwave reactor. The mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; DCM/EtOAc gradient, 0-100%) to afford INT 47 as a yellow solid.
UPLC-MS: MS (ESI): [M+H]+ 487.4, rt = 1.15 min. 1 H NMR (DMSO-d6): δ (ppm) 9.80 (s, 1 H), 8.20 (s, 1 H), 7.66 (t, 1 H), 7.54 (d, 1 H), 7.26-7.18 (m, 3H), 7.1 1 -6.91 (m, 7H), 4.55 (s, 2H), 2.08-1.95 (overlapping s and m, total 4H), 1 .10-1 .01 (m, 2H), 0.85-0.74 (m, 2H).
(4) A/-(3-(6-Amino-5-hydroxypyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2- fluorobenzamide, INT 48
Figure imgf000087_0001
To a solution of INT 47 (1 .16 g, 2.38 mmol) in THF (20 mL) was added Pd-C (1 16 mg). The reaction mixture was hydrogenated at RT and normal pressure for 48 hr. The mixture was diluted with MeOH (10 mL) and filtered over a pad of Celite. The filtrate was concentrated. The residue was suspended in DCM (20 mL) and TFA (0.918 mL, 1 1 .92 mmol) was added. The mixture was stirred at RT for 30 min, then poured into a mixture of saturated aqueous sodium hydrogen carbonate solution and EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to afford INT 48 as a beige solid.
UPLC-MS: MS (ESI): [M+H]+ 397.2, rt = 0.80 min. 1 H NMR (DMSO-d6): δ (ppm) 9.76 (s, 1 H), 8.74 (s, 1 H), 8.02 (s, 1 H), 7.65 (t, 1 H), 7.59-7.48 (m, 1 H), 7.12-7.03 (m, 2H), 6.98- 6.91 (m, 1 H), 6.66 (s, br, 2H), 2.1 1 -1 .94 (overlapping s and m, total 4H), 1 .14-0.98 (m, 2H), 0.87-0.71 (m, 2H). ethyl A/-Boc-4-((methylsulfonyl)oxy)pyrrolidine-2-carboxylate, INT 49
Figure imgf000087_0002
To a solution of (2S,4S)-methyl A/-Boc-4-hydroxypyrrolidine-2-carboxylate (1 1 .50 g, 46.88 mmol) in DCM (100 mL) was added DIPEA (9.70 mL, 55.54 mmol) followed by methanesulfonyl chloride (4.30 mL, 55.18 mmol). The reaction mixture was stirred at RT overnight. More DIPEA (1 .50 mL, 8.59 mmol) and methanesulfonyl chloride (0.60 mL, 7.70 mmol) were added and the reaction mixture was stirred at RT for an additional hour. The mixture was concentrated. The residue was purified by flash chromatography (silica, DCM/EtOAc gradient, 5-15%) followed by a second purification by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-100%) to afford INT 49 as a yellow oil.
MS (ESI): [M+H]+ 324.2. 1 H NMR (CDCI3): δ (ppm) rotamers 5.24 (m, br, 1 H), 4.55-4.48 and 4.44-4.37 (m, total 1 H), 3.84-3.70 (overlapping s and m, total 5H), 3.02 (s, 3H), 2.58-2.47 (m, br, 2H), 1 .48 and 1 .43 (s, total 9 H). Boc-2-(hydroxymethyl)-4-((methylsulfonyl)oxy)pyrrolidine, INT 50
Figure imgf000088_0001
To a solution of INT 49 (12.52 g, 38.72 mmol) in THF (100 mL) at 0 °C was added dropwise lithium borohydride solution (2 M in THF, 67.6 mL, 135.00 mmol). The reaction mixture was stirred overnight and allowed to warm up to RT. The mixture was cooled to 0 °C and water was added slowly. The mixture was extracted with EtOAc, the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The aqueous layer was diluted with saturated aqueous ammonium chloride solution and back-extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The two residues were combined and purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 25-100%; followed by
EtOAc/MeOH gradient, 0-10%) to afford INT 50 as a colorless resin.
MS (ESI): [M+H-tBuf 240.1 . 1 H NMR (CDCI3): δ (ppm) rotamers 5.15-5.10 (m, br, 1 H), 4.37-4.29 and 4.07-3.87 (m, total 2H), 3.81 -3.62 (m, 2H), 3.59-3.47 (m, 2H), 3.00 (s, 3H), 2.37-2.25 and 2.1 1-2.02 (m, total 2H), 1 .40 and 1 .38 (s, total 9H).
(7) (2S,4S)-/V-Boc-2-((fe/ -butyldiphenylsilyl)oxymethyl)-4-((methylsulfonyl)oxy)- pyrrolidine, INT 51
Figure imgf000089_0001
To a solution of INT 50 (1 1 .00 g, 37.24 mmol) in DCM (100 mL) was added imidazole (4.30 g, 63.16 mmol) followed by fe/f-butylchlorodiphenylsilane (1 1 .0 mL, 42.82 mmol). The reaction mixture was stirred at RT for 3 hr. The suspension was filtered over a thin layer of Celite. The filtrate was washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-50%) to afford INT 51 as a colorless oil.
UPLC-MS: MS (ESI): [M+H-tBuf 534.3, rt = 1 .50 min. 1 H NMR (CDCI3): δ (ppm) rotamers 7.69-7.62 (m, 4H), 7.45-7.35 (m, 6H), 5.28-5.16 (m, br, 1 H), 4.17-4.07 and 4.05-3.97 (m, total 1 H), 3.94-3.87 (m, 1 H), 3.87-3.80 (m, 1 H), 3.64-3.50 (m, 2H), 2.91 (s, br, 3H), 2.71-2.61 and 2.40-2.30 (m, total 2H), 1 .43 and 1 .33 (s, total 9H), 1 .06 (s, 9H).
(8) (2S,4f?)-/V-Boc-2-((fe/ -butyldiphenylsilyl)oxymethyl)-4-(cyano)pyrrolidine, INT 52
Figure imgf000089_0002
To a solution of INT 51 (5.06 g, 9.48 mmol) in DMF (75 mL) was added sodium cyanide (1 .39 g, 28.40 mmol). The reaction mixture was stirred at 100 °C for 3 hr. The mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-25%) to afford INT 52 as a colorless resin.
1H NMR (CDCI3): δ (ppm) rotamers 7.65-7.55 (m, 4H), 7.47-7.31 (m, 6H), 4.13-4.05 and 4.02-3.91 and 3.78-3.57 (m, total 5H), 3.39-3.29 (m, 1 H), 2.52-2.21 (m, 2H), 1 .48 and 1.34 (s, total 9H), 1.05 (s, 9H).
(9) (2S,4R)-N-Boc-2-(hydroxymethyl)-4-(cyano)pyrrolidine, INT 53
Figure imgf000090_0001
To a solution of INT 52 (2.95 g, 6.35 mmol) in THF (30 mL) was added TBAF (1 .0 M in THF, 7.5 mL, 7.50 mmol). The reaction mixture was stirred at RT for 2.5 hr. The mixture was concentrated and the residue was taken up in EtOAc. The organic phase was washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0- 100%) to afford INT 53 as a colorless residue.
MS (ESI): [M+H-tBuf 171 .1 . 1 H NMR (CDCI3): δ (ppm) 4.14-3.83 (m, br, 2H), 3.75-3.53 (m, 4H), 3.35-3.19 (m, br, 1 H), 2.40-2.26 and 2.23-2.10 (m, total 2H), 1 .47 (s, 9H).
(10) (2S,4f?)-fe/f-Butyl 2-(((4-amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro- -methylphenyl)pyrimidin-5-yl)oxy)methyl)-4-cyanopyrrolidine-1 -carboxylate, INT 54
Figure imgf000090_0002
To a solution of INT 48 (240 mg, 0.61 mmol) and INT 53 (274 mg, 1 .21 mmol) in THF (15 mL) was added SMOPEX-301 (1 mmol/g, 1 .51 g, 1 .51 mmol). The mixture was heated to 60 °C and DIAD was added dropwise at this temperature. The reaction mixture was stirred at 60 °C for 2 hr. The mixture was filtered through a pad of Celite, the filtrate was concentrated. The residue was purified by flash chromatography (silica;
TBME/EtOAc gradient, 0-100%) to afford INT 54 as a colorless oil.
UPLC-MS: MS (ESI): [M+H]+ 605.3, rt = 1.14 min. (1 1 ) /V-(3-(6-Amino-5-(((2S,4/?)-4-cyanopyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5
clopropyl-2-fluorobenzamide, INT 55
Figure imgf000091_0001
To a solution of INT 54 (content 83%, 313 mg, 0.43 mmol) in DCM (10 mL) was added TFA (1 .0 mL, 12.98 mmol) followed by one drop of water. The reaction mixture was stirred at RT for 1 .5 hr. The mixture was concentrated. The residue was purified by flash chromatography (silica; DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 0-40%) to afford INT 55 as the free amine as a colorless residue.
UPLC-MS: MS (ESI): [M+H]+ 505.3, rt = 0.75 min.
(12) A/-(3-(5-(((2S,4f?)-1 -Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4- -5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000091_0002
To a solution of INT 55 (102 mg, 0.20 mmol) and DIPEA (0.200 mL, 1 .15 mmol) in DCM (4.0 mL) at 0°C was slowly added dropwise acryloyi chloride (0.020 mL, 0.24 mmol). The reaction mixture was stirred at 0°C for 30 min. The mixture was concentrated. The residue was purified by flash chromatography (silica; EtOAc/MeOH gradient, 0-20%), followed by SFC purification to afford Example 39 as white solid after lyophilization. UPLC-MS: MS (ESI): [M+H]+ 559.4, rt = 0.96 min. 1 H NMR (DMSO-d6): δ (ppm) rotamers 9.81 (s, 1 H), 8.21 (d, 1 H), 7.72-7.63 (m, 1 H), 7.57-7.47 (m, 1 H), 7.17-6.91 (m, 5H), 6.48- 6.39 and 6.32-6.21 (m, total 1 H), 6.15-6.05 (m, 1 H), 5.68-5.56 (m, 1 H), 4.29-4.22 and 4.18-4.12 (m, total 1 H), 3.73-3.62 and 3.53-3.45 (m, total 3H), 3.35-3.25 and 3.17-3.08 (m, total 2H), 2.26-1 .95 (overlapping m and s, total 6H), 1 .10-1.01 (m, 2H), 0.85-0.75 (m, 2H).
Example 40
/V-(3-(5-(((2S,4S)-1 -Aci^loyl-4-cyanopyrrolidin-2-yl')rnethoxy')-6-arninopyrirnidin-4-yl')-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
Figure imgf000092_0001
The title compound was prepared according to Scheme 4 following a procedure analogous to Example 39 replacing (2S,4S)-methyl A/-Boc-4-hydroxypyrrolidine-2- carboxylate with (2S,4R)-methyl A/-Boc-4-hydroxypyrrolidine-2-carboxylate in step 5. UPLC-MS: MS (ESI): [M+H]+ 559.4, rt = 0.94 min.
Biological Part
Inhibition of Btk enzymatic activity
The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90 % DMSO. The kinase reactions were started by stepwise addition of 4.5 μΙ per well of peptide/ATP-solution (4 μΜ FITC-Ahx- TSELKKVVALYDYMPMNAND-NH2, 164 μΜ ATP) in kinase buffer (50mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta- glycerophosphate, and 10 μΜ sodium orthovanadate, 18 mM MgCI2, 1 mM MnCI2) and 4.5 μΙ per well of enzyme solution (6.4nM full-lenght human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30°C for 60 minutes and subsequently terminated by addition of 16 μΙ per well of stop solution (100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations.
Figure imgf000093_0001
Example 23 0.001
Example 24 0.0005
Example 25 0.001
Example 26 0.0004
Example 27 0.003
Example 28 0.001
Example 29 0.004
Example 30 0.006
Example 31 0.002
Example 32 0.004
Example 33 0.001
Example 34 0.002
Example 35 0.002
Example 36 0.017
Example 37 0.032
Example 38 0.002
Example 39 0.001
Example 40 0.002
Inhibition of Btk activity in blood
Alternatively, the inhibitory activity of the present compounds in blood was assessed in the following in vitro B cell activation assay. Whole blood was collected from the abdominal aorta of anaesthetized adult male Lewis rats and was anticoagulated with 100 U/ml sodium heparin. Blood was then diluted to 50 % with high glucose DMEM
(Amimed) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L- glutamin, 50 mg/ml dextran 40 and 5% FCS (Fetaclone I, Gibco). Then, 190 μΙ prediluted blood was mixed in 96 well U-bottomed microtiter plates (Nunc) with 10 μΙ of serial dilutions of test compounds in DMSO. Cultures were incubated at 37°C, 5% C02 for 1 hour, then 30 μΙ of rat IL-4 (Beckton-Dickinson, final concentration 5 ng/ml) and goat anti-rat IgM (Serotec, final concentration 15 ug/ml) were added and the cultures were incubated for 24 hours. Activation of B cells was measured by flow cytometry after staining for the B cell subset with PE-Cy5-labeled anti-ratCD45RA (Beckton-Dickinson) and for the activation marker CD86 (PE-labeled anti-rat CD86 (Beckton-Dickinson). All staining procedures were performed at RT for 30 min in the dark in 96-deep well V- bottomed microtiter plates (Corning) with BD Lysing Solution (Beckton-Dickinson). Cytometric data was acquired on a FACScalibur flow cytometer (BD Biosciences) and the subpopulation of lymphocytes were gated according to size and granularity and further analyzed for expression of CD45RA and the activation markers. Data for the inhibition of B cell activation were calculated from the percentage of cells positively stained for activation markers within the CD45RA positive population. Inhibition data were calculated by comparison to control cultures without anti-lgM and IL-4 (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations.
Figure imgf000095_0001
27 0.076
28 0.033
29 0.134
30 0.222
31 0.025
32 0.055
33 0.050
34 0.208
35 0.072
36 0.354
37 0.968
38 0.070
39 0.176
40 0.080
Utilities
Based for example upon the biological test results, compounds of the invention may generally be useful in the treatment of an indication selected from:
Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis,
glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstroem disease.
In a further embodiment, the therapy is selected from a disease which may be treated by an antagonist of Bruton's tyrosine kinase.
In another embodiment, the invention provides a method of treating a disease which is treated by the modulation of Btk- comprising administration of a therapeutically acceptable amount of a compound of formula (I) or a salt thereof. In a further embodiment, the disease is selected from the afore-mentioned lists
Combinations
The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the present invention may be administered separately, by the same or different route of
administration, or together in the same pharmaceutical composition as the other agents.
The compounds of formula (I) may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of alio- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent. For example, the compounds of formula (I) may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a rmTOR inhibitor, e.g. rapamycin, 40-O-(2- hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841 , TAFA-93, biolimus-7 or biolimus-9; an ascomycin having immunosuppressive properties, e.g. ABT-281 , ASM981 , etc.; corticosteroids; cyclophosphamide; azathioprene;
methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N-benzyl-3,4-dihydroxy- benzylidene-cyanoacetamide a-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide
(Tyrphostin AG 490), prodigiosin 25-C (PNU 156804), [4-(4'-hydroxyphenyl)-amino-6,7- dimethoxyquinazoline] (WHI-P131), [4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline] (WHI-P154), [4-(3',5'-dibromo-4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline] WHI-P97, KRX-21 1 , 3-{(3R,4R)-4-methyl-3-[methyl-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1 -yl}-3-oxo-propionitrile, in free form or in a pharmaceutically acceptable salt form, e.g. mono-citrate (also called CP-690,550), or a compound as disclosed in WO 04/052359 or WO 05/066156; sphingosine-1 -phosphate receptor modulators such as FTY720 (fingolimod), or compounds disclosed in WO 2005/000833; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA- 1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5- fluorouracil; or an anti-infectious agent. Further combination partners to a compound of formula (I) may be selected from a PI3K inhibitor (e.g. pan, or alpha, beta, gamma, delta selectives), TNF inhibitors, IL1 beta inhibitors, IL17 inhibitors, and inhibitors of IL6 or IL receptor.
The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula (I) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.
In one embodiment, the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by Btk kinases. Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s). Optionally, the
pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for
administration. ln the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by Btk kinases, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by Btk , wherein the medicament is administered with a compound of formula (I).
The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by Btk, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk , wherein the other therapeutic agent is prepared for administration with a compound of formula (I). The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by Btk , wherein the compound of formula (I) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk, wherein the other therapeutic agent is administered with a compound of formula (I).

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof;
Figure imgf000101_0001
wherein,
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is hydrogen;
R5 is hydrogen or halogen;
or R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R, R', R10 and R1 1 independently from each other stand for H, or C C6 alkyl optionally substituted by C1-C6 alkoxy; or any two of R8, R9, R, R', R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen or C C6 alkoxy;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl, C C6 alkoxy or N,N-di-C C6 alkyl amino; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by CrCf, alkyl.
2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
or R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen; R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
4. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 and R5 are attached to each other and stand for a bond, -CH2-, -CH2-CH2- , - CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; or -CH2-CH2-CH2-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or CrCei alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, C C6 alkyl optionally substituted by hydroxy;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 and R5 are attached to each other and stand for a -CH2-CH2- , or -CH=CH-;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl; or any two of R8, R9, R10 and R1 1 together with the carbon atom to which they are bound may form a 3 - 6 membered saturated carbocyclic ring;
R and R' are hydrogen;
R12 is hydrogen or C C6 alkyl optionally substituted by halogen;
or R12 and any one of R8, R9, R, R', R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, CrCf, alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen;
R12 is hydrogen or C C6 alkyl optionally substituted by halogen;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
7. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8 and R9, independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen;
R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C C6 alkyl.
8. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is halogen;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen; R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen; R8, R9, R10 and R1 1 independently from each other stand for H, or C C6 alkyl;
R and R' are hydrogen;
R12 is hydrogen or C ^ alkyl optionally substituted by halogen;
n is 0 or 1 ; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy.
9. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, or C C6 alkyl optionally substituted by hydroxy;
R2 is fluoro;
R3 is hydrogen;
R4 is hydrogen;
R5 is halogen;
R6 and R7 stand independently from each other for H, C C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;
R8 and R9 independently from each other stand for H, or C C6 alkyl;
R12 and any one of R10 or R1 1 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C C6 alkyl or C C6 alkoxy;
n is 0; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl or C C6 alkoxy; or C2-C6 alkynyl optionally substituted by C C6 alkyl or C C6 alkoxy.
10. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is C C6 alkyl;
R2 is fluoro;
R3 is hydrogen;
R4 is hydrogen;
R5 is fluoro;
R6 and R7 stand independently from each other for H, C3-C6 cycloalkyl, or halogen; R8, R9, R10 and R1 1 stand for H; R12 is hydrogen;
n is 0; and
R13 is C2-C6 alkenyl optionally substituted by C C6 alkyl.
1 1 . A compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from:
N-(3-(5-((1 -Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
(£)-/V-(3-(6-Amino-5-((1 -(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
N-(3-(6-Amino-5-((1-propioloylazetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-
4- cyclopropyl-2-fluorobenzamide;
A/-(3-(6-Amino-5-((1-(but-2-ynoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-((1 -Acryloylpiperidin-4-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
£J-/V-(3-(6-Amino-5-(2-(/ /-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
£J-/V-(3-(6-Amino-5-(2-(4-methoxy-/ /-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-methylbut-2-ynamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
A/-(2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2- methylphenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methyloxirane-2-carboxamide;
A/-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1 -oxoisoquinolin-2(1 - )-yl)phenyl)pyrimidin-
5- yl)oxy)ethyl)-/V-methylacrylamide;
/V-(3-(5-(2-Acrylamidoethoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(2-(/V-ethylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)- 4-cyclopropyl-2-fluorobenzamide; /V-(3-(6-Amino-5-(2-(/V-(2-fluoroethyl)aci lamido
methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-((1 -Aci lamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-(2-Aci lamidopropoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4- cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(but-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)- 4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(/V-methylaci lamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-(2-(/V-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(3-(/V-methylaci lamido)propoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-((1 -Aci loylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-((1 -(but-2-ynoyl)pyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-2-(3-(5-((1 -Aci loylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-
(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
A/-(2-((4-Amino-6-(3-(6-cyclopropyl-1 -oxo-3, 4-dihydroisoquinolin-2(1 H)-yl)-5-fluoro-2-
(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-/ /-methylacrylamide;
/V-(3-(5-(((2S,4/?)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl^ fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
2-(3-(5-(((2S,4/?)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
/V-(3-(5-(((2S,4S)-1 -Aci loyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(6-Amino-5-(((2S,4S)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4- yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-(((2S,4/?)-1-Aci loyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; /V-(3-(6-Amino-5-(((2S,4/?)-1 -(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrim yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(5-((1 -Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro^ methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-/V-(3-(6-Amino-5-((1 -propioloylazetidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2- methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(S)-2-(3-(5-((1 -Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2- (hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1 (2 - )-one;
(/?)-/V-(3-(5-((1-Aci loylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluor^ methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
(/?)-/V-(3-(5-((1-Aci loylpiperidin-3-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fl
methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-(((2/?,3S)-1 -Aci loyl-3-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimi fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
/V-(3-(5-(((2S,4/?)-1 -Aci loyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;
and
/V-(3-(5-(((2S,4S)-1 -Aci loyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5- fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 1 1 and one or more pharmaceutically acceptable carriers.
13. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.
14. A method of modulating Btk activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof.
15. A compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof, for use as a medicament.
16. Use of a compound according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease mediated by Btk.
PCT/IB2014/066422 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives WO2015079417A1 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
MYPI2016701223A MY179059A (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EP20158961.1A EP3689865B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
NZ718835A NZ718835A (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
CA2926908A CA2926908C (en) 2013-11-29 2014-11-28 Amino pyrimidine derivatives
UAA201603623A UA117256C2 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
MYPI2020002915A MY191381A (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
RS20171206A RS56657B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
MX2016006908A MX367911B (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives.
LTEP14821285.5T LT3074386T (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
KR1020227009823A KR102421388B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EP14821285.5A EP3074386B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
CU2016000078A CU24384B1 (en) 2013-11-29 2014-11-28 DERIVATIVES OF N- (3- (6-AMINOPIRIDIN-4-IL) PHENYL) BENZAMIDA AS BTK INHIBITORS
PL17191467T PL3299368T3 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EP17191467.4A EP3299368B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
ES14821285.5T ES2655527T3 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
JP2016535053A JP6342495B2 (en) 2013-11-29 2014-11-28 Novel aminopyrimidine derivatives
MA39055A MA39055B1 (en) 2013-11-29 2014-11-28 New aminopyrimidine derivatives
CN201910288376.XA CN110172056B (en) 2013-11-29 2014-11-28 Aminopyrimidine derivatives
NO14821285A NO3074386T3 (en) 2013-11-29 2014-11-28
PL14821285T PL3074386T3 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
TN2016000128A TN2016000128A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives.
DK14821285.5T DK3074386T3 (en) 2013-11-29 2014-11-28 Novel aminopyrimidine derivatives
BR112016010397-1A BR112016010397B1 (en) 2013-11-29 2014-11-28 AMINO PYRIMIDINE DERIVATIVES, THEIR USES AND PHARMACEUTICAL COMPOSITION
AP2016009158A AP2016009158A0 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EA201691125A EA031218B1 (en) 2013-11-29 2014-11-28 Amino pyrimidine derivatives
AU2014356069A AU2014356069B2 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
SI201430536T SI3074386T1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
CN201480058515.5A CN105683181B (en) 2013-11-29 2014-11-28 New aminopyridine derivative
EP23161775.4A EP4219478A1 (en) 2013-11-29 2014-11-28 Method of preparing amino pyrimidine derivatives
KR1020167013830A KR102380539B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
ZA2016/02275A ZA201602275B (en) 2013-11-29 2016-04-05 Novel amino pyrimidine derivatives
IL244943A IL244943B (en) 2013-11-29 2016-04-06 N-[3-(5-oxy-6-amino-pyrimidin-4-yl)phenyl]benzamide derivatives and pharmaceutical compositions comprising them
PH12016500791A PH12016500791B1 (en) 2013-11-29 2016-04-28 Novel amino pyrimidine derivatives
CR20160244A CR20160244A (en) 2013-11-29 2016-05-27 Novel Amino Pyrimidine Derivatives
HK16111636.9A HK1223368A1 (en) 2013-11-29 2016-10-06 Novel amino pyrimidine derivatives
CY20171101345T CY1119705T1 (en) 2013-11-29 2017-12-22 New aminopyrimidine derivatives
HRP20171999TT HRP20171999T1 (en) 2013-11-29 2017-12-27 Novel amino pyrimidine derivatives
CY20201100478T CY1122924T1 (en) 2013-11-29 2020-05-25 NEW AMINOPYRIMIDINE DERIVATIVES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP13195081.8 2013-11-29

Publications (1)

Publication Number Publication Date
WO2015079417A1 true WO2015079417A1 (en) 2015-06-04

Family

ID=49674216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Country Status (43)

Country Link
US (6) US9512084B2 (en)
EP (4) EP3074386B1 (en)
JP (2) JP6342495B2 (en)
KR (2) KR102421388B1 (en)
CN (2) CN110172056B (en)
AP (1) AP2016009158A0 (en)
AR (1) AR098549A1 (en)
AU (1) AU2014356069B2 (en)
BR (1) BR112016010397B1 (en)
CA (1) CA2926908C (en)
CL (1) CL2016001055A1 (en)
CR (1) CR20160244A (en)
CU (1) CU24384B1 (en)
CY (3) CY1119705T1 (en)
DK (3) DK3074386T3 (en)
EA (1) EA031218B1 (en)
EC (1) ECSP16054826A (en)
ES (3) ES2947770T3 (en)
FI (1) FI3689865T3 (en)
HK (2) HK1223368A1 (en)
HR (3) HRP20230585T1 (en)
HU (3) HUE037588T2 (en)
IL (1) IL244943B (en)
JO (1) JO3314B1 (en)
LT (3) LT3299368T (en)
MA (1) MA39055B1 (en)
MX (1) MX367911B (en)
MY (2) MY179059A (en)
NO (1) NO3074386T3 (en)
NZ (1) NZ718835A (en)
PE (1) PE20160869A1 (en)
PH (1) PH12016500791B1 (en)
PL (3) PL3689865T3 (en)
PT (3) PT3299368T (en)
RS (3) RS56657B1 (en)
SI (3) SI3689865T1 (en)
SV (1) SV2016005206A (en)
TN (1) TN2016000128A1 (en)
TW (1) TWI652261B (en)
UA (1) UA117256C2 (en)
UY (1) UY35858A (en)
WO (1) WO2015079417A1 (en)
ZA (1) ZA201602275B (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016164580A1 (en) * 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016164731A2 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2018102787A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US10221245B2 (en) 2013-03-16 2019-03-05 Novartis Ag Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US10357514B2 (en) 2014-04-07 2019-07-23 The Trustees Of The University Of Pennsylvania Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
US10457647B2 (en) 2013-11-29 2019-10-29 Novartis Ag Amino pyrimidine derivatives
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020092854A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020102770A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
EP3660042A1 (en) 2014-07-31 2020-06-03 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020234782A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
WO2020234779A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
WO2020234781A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
WO2022162513A1 (en) 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023031840A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
WO2023111802A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
WO2023161887A1 (en) 2022-02-28 2023-08-31 Novartis Ag Remibrutinib for use in the treatment of hidradenitis suppurativa
CN117024354A (en) * 2023-10-08 2023-11-10 天津凯莱英制药有限公司 Preparation method of Rui Mi Buti Ni
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024028782A1 (en) 2022-08-03 2024-02-08 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
RU2828460C2 (en) * 2019-05-23 2024-10-14 Новартис Аг Crystalline forms of btk inhibitor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113796A1 (en) * 2017-11-06 2020-06-10 Lilly Co Eli BRUTON TYROSINE KINASE (BTK) INHIBITING COMPOUNDS
CN108069911A (en) * 2017-12-14 2018-05-25 中国药科大学 6- amino -2- phenyl pyrimidine classes compound, preparation method and medical usage
WO2022033569A1 (en) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 Crystal forms of benzamide compounds and preparation method therefor

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038561A1 (en) 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
WO2002102790A1 (en) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. N-formyl hydroxylamine compounds as inhibitors of pdf
WO2003082859A1 (en) 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
WO2010000633A1 (en) 2008-07-02 2010-01-07 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
WO2010100070A1 (en) * 2009-03-02 2010-09-10 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013083666A1 (en) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
KR101357524B1 (en) 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 Certain Substituted Amides, Method of Making, And Method of Use Thereof
JP2010502751A (en) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド Kinase inhibitors and methods of using and identifying kinase inhibitors
AR063946A1 (en) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc CERTAIN REPLACED PIRIMIDINS, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2680589A1 (en) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
ES2554615T3 (en) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Substituted amides, method of preparation and use as Btk inhibitors
MX2011000661A (en) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors.
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
CA2748414A1 (en) 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
AU2011219764A1 (en) * 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (en) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
MX355728B (en) 2011-05-17 2018-04-27 Univ California Kinase inhibitors.
BR112013030442B1 (en) 2011-06-10 2021-11-09 Merck Patent Gmbh PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY, THEIR USES, COMPOSITION, AND KIT
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
KR20140058543A (en) 2011-07-08 2014-05-14 노파르티스 아게 Novel pyrrolo pyrimidine derivatives
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
AR088570A1 (en) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
MX2015001802A (en) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors.
CA2887435A1 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038561A1 (en) 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
WO2002102790A1 (en) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. N-formyl hydroxylamine compounds as inhibitors of pdf
WO2003082859A1 (en) 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
WO2010000633A1 (en) 2008-07-02 2010-01-07 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
WO2010100070A1 (en) * 2009-03-02 2010-09-10 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013083666A1 (en) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927184B2 (en) 2013-03-16 2021-02-23 Novartis Ag Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US10221245B2 (en) 2013-03-16 2019-03-05 Novartis Ag Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US10457647B2 (en) 2013-11-29 2019-10-29 Novartis Ag Amino pyrimidine derivatives
US11180460B2 (en) 2013-11-29 2021-11-23 Novartis Ag Amino pyrimidine derivatives
US11673868B2 (en) 2013-11-29 2023-06-13 Novartis Ag Amino pyrimidine derivatives
US10357514B2 (en) 2014-04-07 2019-07-23 The Trustees Of The University Of Pennsylvania Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3660042A1 (en) 2014-07-31 2020-06-03 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3967709A1 (en) 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016164580A1 (en) * 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US11149076B2 (en) 2015-04-08 2021-10-19 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
EP4056588A1 (en) 2015-04-08 2022-09-14 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
WO2016164731A2 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP4424322A2 (en) 2015-12-17 2024-09-04 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
US11026976B2 (en) 2016-10-07 2021-06-08 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
USRE49847E1 (en) 2016-10-07 2024-02-27 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
US11872249B2 (en) 2016-10-07 2024-01-16 Novartis Ag Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
WO2018102787A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP4279136A2 (en) 2016-12-03 2023-11-22 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US11944647B2 (en) 2017-06-02 2024-04-02 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US11623961B2 (en) 2017-11-01 2023-04-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
US12006356B2 (en) 2017-12-15 2024-06-11 Juno Therapeutics, Inc. Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020092854A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020102770A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
EP4427810A2 (en) 2018-11-30 2024-09-11 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
CN113811301A (en) * 2019-05-23 2021-12-17 诺华股份有限公司 Methods of treating sjogren's syndrome using bruton's tyrosine kinase inhibitors
RU2828460C2 (en) * 2019-05-23 2024-10-14 Новартис Аг Crystalline forms of btk inhibitor
EP4442321A2 (en) 2019-05-23 2024-10-09 Novartis AG Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2020234781A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2020234779A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
WO2020234782A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022162513A1 (en) 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023031840A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
WO2023111802A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
WO2023161887A1 (en) 2022-02-28 2023-08-31 Novartis Ag Remibrutinib for use in the treatment of hidradenitis suppurativa
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024028782A1 (en) 2022-08-03 2024-02-08 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
CN117024354B (en) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 Preparation method of Rui Mi Buti Ni
CN117024354A (en) * 2023-10-08 2023-11-10 天津凯莱英制药有限公司 Preparation method of Rui Mi Buti Ni

Also Published As

Publication number Publication date
TW201609666A (en) 2016-03-16
BR112016010397B1 (en) 2023-04-11
AP2016009158A0 (en) 2016-04-30
MX2016006908A (en) 2016-08-17
EP3689865A1 (en) 2020-08-05
JO3314B1 (en) 2019-03-13
TN2016000128A1 (en) 2017-10-06
MY191381A (en) 2022-06-22
US20230312483A1 (en) 2023-10-05
PH12016500791A1 (en) 2016-06-13
EP3074386A1 (en) 2016-10-05
DK3074386T3 (en) 2018-01-22
UA117256C2 (en) 2018-07-10
PT3299368T (en) 2020-05-28
ES2791525T3 (en) 2020-11-04
NZ718835A (en) 2021-12-24
AU2014356069A1 (en) 2016-05-05
US11180460B2 (en) 2021-11-23
ES2947770T3 (en) 2023-08-18
US9512084B2 (en) 2016-12-06
MY179059A (en) 2020-10-26
PL3074386T3 (en) 2018-03-30
IL244943B (en) 2020-04-30
ZA201602275B (en) 2017-08-30
CN105683181B (en) 2019-04-23
SI3299368T1 (en) 2020-07-31
TWI652261B (en) 2019-03-01
ECSP16054826A (en) 2017-10-31
US20200010426A1 (en) 2020-01-09
AU2014356069B2 (en) 2017-06-15
PE20160869A1 (en) 2016-09-08
PH12016500791B1 (en) 2016-06-13
IL244943A0 (en) 2016-05-31
CU24384B1 (en) 2019-03-04
AR098549A1 (en) 2016-06-01
NO3074386T3 (en) 2018-03-10
EP3299368A1 (en) 2018-03-28
LT3299368T (en) 2020-05-25
CN105683181A (en) 2016-06-15
HRP20230585T1 (en) 2023-09-01
HUE049794T2 (en) 2020-10-28
DK3299368T3 (en) 2020-05-25
RS64275B1 (en) 2023-07-31
RS56657B1 (en) 2018-03-30
US20220041561A1 (en) 2022-02-10
HUE037588T2 (en) 2018-09-28
CU20160078A7 (en) 2016-09-30
MA39055B1 (en) 2018-10-31
LT3689865T (en) 2023-07-10
MA39055A1 (en) 2018-02-28
EA201691125A1 (en) 2016-09-30
PT3689865T (en) 2023-06-16
CY1122924T1 (en) 2021-10-29
KR20160088877A (en) 2016-07-26
DK3689865T3 (en) 2023-06-19
CA2926908A1 (en) 2015-06-04
HK1252317A1 (en) 2019-05-24
CN110172056A (en) 2019-08-27
EP3074386B1 (en) 2017-10-11
SI3689865T1 (en) 2023-07-31
PL3689865T3 (en) 2023-07-31
ES2655527T3 (en) 2018-02-20
KR20220044370A (en) 2022-04-07
CY1119705T1 (en) 2018-06-27
JP6667573B2 (en) 2020-03-18
LT3074386T (en) 2017-12-27
KR102421388B1 (en) 2022-07-18
HRP20171999T1 (en) 2018-02-09
EP4219478A1 (en) 2023-08-02
KR102380539B1 (en) 2022-03-29
CL2016001055A1 (en) 2016-10-28
HK1223368A1 (en) 2017-07-28
UY35858A (en) 2015-06-30
CY1126056T1 (en) 2023-11-15
HRP20200775T1 (en) 2020-07-24
HUE062248T2 (en) 2023-10-28
US20150152068A1 (en) 2015-06-04
CN110172056B (en) 2022-04-19
BR112016010397A8 (en) 2020-04-22
CR20160244A (en) 2016-07-29
US20180251432A1 (en) 2018-09-06
US20160235746A1 (en) 2016-08-18
SV2016005206A (en) 2016-11-21
FI3689865T3 (en) 2023-06-12
MX367911B (en) 2019-09-11
PL3299368T3 (en) 2020-08-10
EP3689865B1 (en) 2023-03-29
EA031218B1 (en) 2018-12-28
PT3074386T (en) 2017-11-15
JP2016538313A (en) 2016-12-08
RS60251B1 (en) 2020-06-30
EP3299368B1 (en) 2020-02-26
JP6342495B2 (en) 2018-06-13
JP2018141005A (en) 2018-09-13
US11673868B2 (en) 2023-06-13
SI3074386T1 (en) 2018-02-28
CA2926908C (en) 2021-10-26
US10457647B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
US11673868B2 (en) Amino pyrimidine derivatives
US9233111B2 (en) Pyrrolo pyrimidine derivatives
US20240208947A1 (en) Jak1 selective inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14821285

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 244943

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2926908

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IDP00201602662

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 12016500791

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2014356069

Country of ref document: AU

Date of ref document: 20141128

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 139550140003002102

Country of ref document: IR

REEP Request for entry into the european phase

Ref document number: 2014821285

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014821285

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 39055

Country of ref document: MA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016010397

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167013830

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000683-2016

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 16138728

Country of ref document: CO

Ref document number: MX/A/2016/006908

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016535053

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CR2016-000244

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201691125

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201603623

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112016010397

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160509